<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">89368</article-id>
<article-id pub-id-type="doi">10.7554/eLife.89368</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.89368.1</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.1</article-version>
</article-version-alternatives>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Genetics and Genomics</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Neuroscience</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Distinctive Whole-brain Cell-Types Strongly Predict Tissue Damage Patterns in Eleven Neurodegenerative Disorders</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Pak</surname>
<given-names>Veronika</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5090-6140</contrib-id>
<name>
<surname>Adewale</surname>
<given-names>Quadri</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3466-6620</contrib-id>
<name>
<surname>Bzdok</surname>
<given-names>Danilo</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a5">5</xref>
<xref ref-type="aff" rid="a6">6</xref>
<xref ref-type="aff" rid="a7">7</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4008-2672</contrib-id>
<name>
<surname>Dadar</surname>
<given-names>Mahsa</given-names>
</name>
<xref ref-type="aff" rid="a8">8</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0583-5811</contrib-id>
<name>
<surname>Zeighami</surname>
<given-names>Yashar</given-names>
</name>
<xref ref-type="aff" rid="a8">8</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9345-0347</contrib-id>
<name>
<surname>Iturria-Medina</surname>
<given-names>Yasser</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a4">4</xref>
<xref ref-type="aff" rid="a5">5</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<aff id="a1"><label>1</label><institution>Department of Neurology and Neurosurgery, McGill University</institution>, Montreal, Quebec, <country>Canada</country></aff>
<aff id="a2"><label>2</label><institution>McConnell Brain Imaging Centre, Montreal Neurological Institute</institution>, Montreal, Quebec, <country>Canada</country></aff>
<aff id="a3"><label>3</label><institution>Ludmer Centre for Neuroinformatics &amp; Mental Health</institution>, Montreal, Quebec, <country>Canada</country></aff>
<aff id="a4"><label>4</label><institution>McGill Centre for Studies in Aging</institution>, Montreal Quebec, <country>Canada</country></aff>
<aff id="a5"><label>5</label><institution>Department of Biomedical Engineering, McGill University</institution>, Montreal, Quebec, <country>Canada</country></aff>
<aff id="a6"><label>6</label><institution>School of Computer Science, McGill University</institution>, Montreal, Quebec, <country>Canada</country></aff>
<aff id="a7"><label>7</label><institution>Mila – Quebec Artificial Intelligence Institute</institution>, Montreal, Quebec, <country>Canada</country></aff>
<aff id="a8"><label>8</label><institution>The Douglas Research Center</institution>, Montreal, Quebec, <country>Canada</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Fornito</surname>
<given-names>Alex</given-names>
</name>
<role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Monash University</institution>
</institution-wrap>
<city>Clayton</city>
<country>Australia</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Wong</surname>
<given-names>Ma-Li</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution>State University of New York Upstate Medical University</institution>
</institution-wrap>
<city>Syracuse</city>
<country>United States of America</country>
</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>*</label>Correspondence to: Yasser Iturria-Medina, 3801 University Street, room NW312, Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada H3A 2B4. <email>yasser.iturriamedina@mcgill.ca</email>.</corresp>
</author-notes>
<pub-date date-type="original-publication" iso-8601-date="2023-09-19">
<day>19</day>
<month>09</month>
<year>2023</year>
</pub-date>
<volume>12</volume>
<elocation-id>RP89368</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2023-05-30">
<day>30</day>
<month>05</month>
<year>2023</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2023-06-09">
<day>09</day>
<month>06</month>
<year>2023</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.06.08.544227"/>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2023, Pak et al</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Pak et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-89368-v1.pdf"/>
<abstract>
<title>Abstract</title>
<p>For over a century, brain research narrative has mainly centered on neuron cells. Accordingly, most whole-brain neurodegenerative studies focus on neuronal dysfunction and their selective vulnerability, while we lack comprehensive analyses of other major cell-types’ contribution. By unifying spatial gene expression, structural MRI, and cell deconvolution, here we describe how the human brain distribution of canonical cell-types extensively predicts tissue damage in eleven neurodegenerative disorders, including early- and late-onset Alzheimer’s disease, Parkinson’s disease, dementia with Lewy bodies, amyotrophic lateral sclerosis, frontotemporal dementia, and tauopathies. We reconstructed comprehensive whole-brain reference maps of cellular abundance for six major cell-types and identified characteristic axes of spatial overlapping with atrophy. Our results support the strong mediating role of non-neuronal cells, primarily microglia and astrocytes, on spatial vulnerability to tissue loss in neurodegeneration, with distinct and shared across-disorders pathomechanisms. These observations provide critical insights into the multicellular pathophysiology underlying spatiotemporal advance in neurodegeneration. Notably, they also emphasize the need to exceed the current neuro-centric view of brain diseases, supporting the imperative for cell-specific therapeutic targets in neurodegeneration.</p>
</abstract>
<abstract abstract-type="teaser">
<title>One Sentence Summary</title>
<p>Major cell-types distinctively associate with spatial vulnerability to tissue loss in eleven neurodegenerative disorders.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>brain canonical cell-types</kwd>
<kwd>cellular vulnerability</kwd>
<kwd>imaging transcriptomics</kwd>
<kwd>structural MRI</kwd>
<kwd>Alzheimer’s disease</kwd>
<kwd>Parkinson’s disease</kwd>
<kwd>amyotrophic lateral sclerosis</kwd>
<kwd>frontotemporal dementia</kwd>
<kwd>dementia with Lewy bodies</kwd>
</kwd-group>

</article-meta>
<notes>
<notes notes-type="competing-interest-statement">
<title>Competing Interest Statement</title><p>The authors have declared no competing interest.</p></notes>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Neurodegenerative diseases (NDs) are characterised by substantial neuronal loss in the central and peripheral nervous system<sup><xref ref-type="bibr" rid="c1">1</xref></sup>. In dementia-related conditions like Alzheimer’s disease (AD), frontotemporal dementia (FTD), and dementia with Lewy bodies (DLB), neurodegeneration can lead to progressive damage in brain regions related with memory, behaviour, and cognition<sup><xref ref-type="bibr" rid="c2">2</xref></sup>. Other NDs are thought to primarily affect the locomotor system, including motor neurons in amyotrophic lateral sclerosis (ALS) and nigrostriatal dopaminergic circuitry in Parkinson’s disease (PD)<sup><xref ref-type="bibr" rid="c3">3</xref></sup>. Although each disorder has its own distinct etiology, progression, affected brain areas, and clinical manifestations, transcriptomics analyses support that most of them share molecular and cellular mechanisms<sup><xref ref-type="bibr" rid="c4">4</xref>-<xref ref-type="bibr" rid="c7">7</xref></sup>.</p>
<p>While research has been mainly focused on neuronal dysfunction, supporting cells such as astrocytes, microglia, oligodendrocytes, cells of the vascular and peripheral immune systems and their contribution to the disease pathology are gaining more recognition<sup><xref ref-type="bibr" rid="c8">8</xref>-<xref ref-type="bibr" rid="c10">10</xref></sup>. Depending on the disease stage, non-neuronal cells in the brain can play a dual role, both protective and detrimental, by producing neuroprotective and pro-inflammatory factors. Thus, their complex response can have both positive and negative effects on neuronal health and survival. For example, the activation of glial cells can lead to metabolic stress, disruption of the blood-brain barrier, and reduced energy, all of which contribute to increased neuronal death<sup><xref ref-type="bibr" rid="c11">11</xref>-<xref ref-type="bibr" rid="c15">15</xref></sup>. In AD, for example, overproduction of pro-inflammatory cytokines leads to the accumulation of amyloid-β and tau plaques, which are known as the major hallmarks of the disease<sup><xref ref-type="bibr" rid="c12">12</xref>, <xref ref-type="bibr" rid="c16">16</xref>, <xref ref-type="bibr" rid="c17">17</xref></sup>. This process depends on the innate immune system, which includes microglia and astrocytes<sup><xref ref-type="bibr" rid="c18">18</xref>, <xref ref-type="bibr" rid="c19">19</xref></sup>. Peripheral interference from systemic inflammation or the gut microbiome can also alter the progression of neuronal loss<sup><xref ref-type="bibr" rid="c20">20</xref></sup>. Growing evidence suggests that these immune-mediated events is a driving force behind the wide range of NDs<sup><xref ref-type="bibr" rid="c18">18</xref>, <xref ref-type="bibr" rid="c19">19</xref>, <xref ref-type="bibr" rid="c21">21</xref>, <xref ref-type="bibr" rid="c22">22</xref></sup>. Yet, the exact bases behind how these processes contribute to selective neuronal loss across brain regions remain unclear.</p>
<p>Recent studies have suggested that brain spatial patterns in gene expression are associated with regional vulnerability to some neurodegenerative disorders and their corresponding tissue atrophy distributions<sup><xref ref-type="bibr" rid="c23">23</xref>-<xref ref-type="bibr" rid="c26">26</xref></sup>. Comparison of transcriptomic patterns in middle temporal gyrus across various brain diseases showed cell-type expression signature unique for neurodegenerative diseases<sup><xref ref-type="bibr" rid="c7">7</xref></sup>. Although single-cell transcriptomics and proteomics analyses have advanced our knowledge of cell-type compositions associated with pathology in neurodegeneration<sup><xref ref-type="bibr" rid="c27">27</xref>-<xref ref-type="bibr" rid="c29">29</xref></sup>, these are invariably restricted to a few isolated brain regions, usually needing to be preselected at hand for each specific disease. Due to the invasive nature of tissue acquisition/mapping and further technical limitations for covering extended areas<sup><xref ref-type="bibr" rid="c30">30</xref></sup>, no whole-brain maps for the abundance of cell populations in humans are currently available, constraining the analysis of large-scale cellular vulnerabilities in neurological diseases. Accordingly, how spatial cell-types distributions relate to stereotypic regional damages in neurodegeneration remain largely unclear<sup><xref ref-type="bibr" rid="c31">31</xref></sup>.</p>
<p>Here, we extend previous analysis of cellular-based spatiotemporal vulnerability in neurodegeneration in three fundamental ways. First, we use transcriptomics, structural magnetic resonance imaging (MRI), and advanced cell deconvolution to construct whole-brain reference maps of cellular abundance for six canonical cell-types: neurons, astrocytes, oligodendrocytes, microglia, endothelial cells, and oligodendrocyte precursors. Second, we describe the spatial associations of each canonical cell-type with atrophy maps from eleven low-to-high prevalent neurodegenerative conditions, including early- and late-AD, PD, FTD, DLB, ALS, tau, and TAR DNA-binding protein 43 (TDP43) pathologies. Third, we identify distinctive cell-cell and disease-disease axes of spatial susceptibility in neurodegeneration, obtaining new insights about across-diseases (dis)similarities in underlying pathological cellular systems. We confirm that non-neuronal cells express substantial vulnerability to tissue loss and spatial brain alterations in most studied neurodegenerative conditions, with distinct and shared across-cells and across-diseases mechanisms. This study aids in unraveling the commonalities across a myriad of dissimilar neurological diseases, while also revealing cell-type specific patterns conferring increased vulnerability or resilience to each examined disorder. For further translation and validation of our findings, all resulting analytic tools and cells abundance maps are shared with the scientific and clinical community.</p>
</sec>
<sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>Multimodal data origin and unification approach</title>
<p>We obtained whole-brain voxel-wise atrophy maps for eleven neurodegenerative conditions, including early- and late-onset Alzheimer’s disease (EOAD and LOAD, respectively), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), dementia with Lewy bodies (DLB) and dementia-related pathologies (presenilin-1, TDP43A, TDP43C, 3RTau, and 4RTau; see <italic>Materials and Methods, Disease-specific atrophy maps</italic> subsection)<sup><xref ref-type="bibr" rid="c32">32</xref>, <xref ref-type="bibr" rid="c33">33</xref></sup>. Pathological diagnosis confirmation was performed for AD and related dementias (DLB, presenilin-1, TDP43A, TDP43C, 3RTau, and 4RTau; <sup><xref ref-type="bibr" rid="c32">32</xref></sup>), while PD, ALS, and FTD were diagnosed based on clinical and/or neuroimaging criteria<sup><xref ref-type="bibr" rid="c34">34</xref>, <xref ref-type="bibr" rid="c35">35</xref></sup>, with some ALS patients being histologically confirmed <italic>post-mortem</italic><sup><xref ref-type="bibr" rid="c35">35</xref></sup>. Change in tissue density in the atrophy maps was previously measured by voxel- and deformation-based morphometry (VBM and DBM; <italic>Materials and Methods, Disease-specific atrophy maps</italic> subsection) applied to structural T1-weighted MR images, and expressed as a t-score per voxel (relatively low negative values indicate greater GM tissue loss/atrophy; <sup><xref ref-type="bibr" rid="c36">36</xref>, <xref ref-type="bibr" rid="c37">37</xref></sup>). All maps are registered to the Montreal Neurological Institute (MNI) brain space <sup><xref ref-type="bibr" rid="c38">38</xref></sup>. In addition, we obtained bulk transcriptomic data for the adult human brain from the Allen Human Brain Atlas (AHBA)<sup><xref ref-type="bibr" rid="c39">39</xref></sup>. This included high-resolution coverage of nearly the entire brain, measuring expression levels for over 20,000 genes from 3702 distinct tissue samples of six post-mortem specimens, and detailed structural MRI data (see <italic>Materials and Methods, Mapping gene expression data</italic>) <sup><xref ref-type="bibr" rid="c39">39</xref></sup>.</p>
<p>Using previously validated approaches to infer gene expression levels (in AHBA data) at not-sampled brain locations<sup><xref ref-type="bibr" rid="c40">40</xref></sup>, mRNA expression levels were completed for all gray matter (GM) voxels in the standardized MNI brain space<sup><xref ref-type="bibr" rid="c38">38</xref></sup>. Next, at each GM location, densities for multiple canonical cell-types were estimated using the Brain Cell-type Specific Gene Expression Analysis software (BRETIGEA)<sup><xref ref-type="bibr" rid="c41">41</xref></sup>. This deconvolution method<sup><xref ref-type="bibr" rid="c41">41</xref></sup> accurately estimates cell proportions from bulk mRNA for six major cell-types (<xref rid="fig1" ref-type="fig">Fig. 1C</xref>): neurons, astrocytes, oligodendrocytes, microglia, endothelial cells, and oligodendrocyte precursor cells (OPCs). Overall, atrophy levels for eleven neurodegenerative disorders and proportion values for six major cell-types were unified at matched and standardized locations (MNI space) covering the brain’s whole gray matter (see <xref rid="fig1" ref-type="fig">Fig. 1</xref> for schematic description).</p>
<fig id="fig1" position="float" fig-type="figure">
<label>Figure 1.</label>
<caption><p>Schematic approach for whole-brain cells proportions vulnerability analysis in neurodegeneration. (<bold>A</bold>) Gene expression levels in the AHBA were derived from 3072 distinct tissue samples of six post-mortem human brains. (<bold>B</bold>) Microarray gene expression data was inferred for each unsampled GM voxel and together with AHBA data was mapped into volumetric MNI space resulting in the brain-wide transcriptional atlas. Deconvolution machine learning algorithm for bulk RNA expression levels was applied to the transcriptional atlas with using well-known cell-type-specific gene markers. (<bold>C</bold>) Comprehensive volumetric maps showing reconstructed distributions of six canonical cell-types, including neurons, astrocytes, microglia, endothelial cells, oligodendrocytes and OPCs, across all gray matter voxels in the brain (see <italic>Materials and Methods, Cell-type proportion estimation</italic> subsection). At each voxel, red and blue colors indicate high and low proportion densities, respectively. (<bold>D</bold>) Associations between cell-types proportions from each density map and atrophy values in eleven neurodegenerative conditions were analysed in 118 predefined by the AAL atlas regions. Created with <ext-link ext-link-type="uri" xlink:href="http://BioRender.com">BioRender.com</ext-link></p></caption>
<graphic xlink:href="544227v1_fig1.tif" mimetype="image" mime-subtype="tiff"/>
<permissions>
<copyright-statement>© 2024, BioRender Inc</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>BioRender Inc</copyright-holder>
<license><license-p>Any parts of this image created with <ext-link ext-link-type="uri" xlink:href="https://www.biorender.com/">BioRender</ext-link> are not made available under the same license as the Reviewed Preprint, and are © 2024, BioRender Inc.</license-p></license>
</permissions></fig>
<p>We hypothesized (and tested in next subsections) that brain tissue damages in neurodegenerative disorders are associated with distinctive patterns of cells distributions, with alterations on major cell-types playing a key role on the development of each disorder and representing a direct f ctor contributing to brain dysfunction.</p>
</sec>
<sec id="s2b">
<title>Uncovering spatial associations between cell-type abundances and tissue damage in neurodegeneration</title>
<p>First, we investigated whether stereotypic brain atrophy patterns in neurodegenerative disorders have systematic associations with the spatial distribution of canonical cell-type populations. For each disease and cell-type pair, the non-linear Spearman correlation was calculated with paired atrophy-cell proportion values across 118 cortical and subcortical regions defined by the automated anatomical labelling (AAL) atlas (Table S1; <sup><xref ref-type="bibr" rid="c42">42</xref></sup>). The results (<xref rid="fig2" ref-type="fig">Figs. 2A-L</xref>) show clear associations for all the studied diseases, suggesting extensive cell-types related tissue damage vulnerability in NDs. We confirmed that the observed relationships are independent of brain parcellation, obtaining equivalent results for a different brain parcellation (i.e., DKT atlas <sup><xref ref-type="bibr" rid="c43">43</xref></sup>; see Fig. S1).</p>
<fig id="fig2" position="float" fig-type="figure">
<label>Figure 2.</label>
<caption><p>Spatial associations between tissue integrity and cell-types proportions for eleven neurodegenerative conditions. A-K) Strongest Spearman correlations for EOAD, LOAD, DLB, PS1, 3RTau, 4RTau, TDP43A, TDP43C, FTD, PD, and ALS, respectively. L) All pairwise cells-diseases correlation values. In A-K, each dot represents a GM region from the AAL atlas (Table S1; see Fig. S1 for equivalent results for the DKT parcellation). Lower tissue integrity score indicates greater GM loss/atrophy. Notice how astrocyte density significantly correlates with increase in tissue loss in EOAD, DLB, PS1, TDP43C, and FTD (A, C, D, H, I; P &lt; 0.001). Tissue loss was also associated with increase in microglial proportion in LOAD, 3RTau, 4RTau, and TDP43A (B, E, F, G; P &lt; 0.001), and increase in oligodendrocytes in PD (J; p &lt; 0.001). Increase in neuronal proportion showed association with decrease in atrophy and tissue enrichment in ALS (K; p &lt; 0.001).</p></caption>
<graphic xlink:href="544227v1_fig2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>As shown in <xref rid="fig2" ref-type="fig">Figs. 2A-L</xref>, astrocytes and microglia cell occurrences presented the strongest spatial associations with atrophy in most neurodegenerative conditions, particularly for EOAD, LOAD, DLB, presenilin-1, 3RTau, 4RTau, TDP43A, TDP43C and FTD (all P &lt; 0.001). Astrocytes are involved in neuronal support, extracellular homeostasis, and inflammatory regulation in response to injury, and show high susceptibility to senescence and oxidative damage<sup><xref ref-type="bibr" rid="c44">44</xref>, <xref ref-type="bibr" rid="c45">45</xref></sup>. Astrocytes also play an important role in the maintenance of the blood-brain barrier (BBB)<sup><xref ref-type="bibr" rid="c46">46</xref></sup>. Atrophy patterns in cortical regions of genetic FTD was shown to be associated with higher expression of astrocytes- and endothelial cells-related genes<sup><xref ref-type="bibr" rid="c26">26</xref></sup>. There is evidence of endothelium degeneration and vascular dysfunction in AD and PD<sup><xref ref-type="bibr" rid="c47">47</xref>, <xref ref-type="bibr" rid="c48">48</xref></sup>. This degeneration may lead to disruption of the BBB, which would allow harmful substances to enter the brain, including inflammatory molecules and toxic aggregated proteins<sup><xref ref-type="bibr" rid="c48">48</xref>, <xref ref-type="bibr" rid="c49">49</xref></sup>. Furthermore, the endothelium plays a key role in delivering oxygen and nutrients. The disruption of this process in neurodegeneration may lead to impaired brain function and cognitive decline<sup><xref ref-type="bibr" rid="c14">14</xref>, <xref ref-type="bibr" rid="c50">50</xref></sup>.</p>
<p>Similarly involved in neuronal support, microglial cells are the resident macrophages of the central nervous system and key players in the pathology of neurodegenerative conditions including EOAD, LOAD, PD, FTD and ALS<sup><xref ref-type="bibr" rid="c12">12</xref>, <xref ref-type="bibr" rid="c51">51</xref>, <xref ref-type="bibr" rid="c52">52</xref></sup>. Besides its many critical specializations, microglial activation involvement in prolonged neuroinflammation is of particular relevance in NDs<sup><xref ref-type="bibr" rid="c11">11</xref>,<xref ref-type="bibr" rid="c53">53</xref></sup>. At earlier stages of AD, increased population of microglia and astrocytes (microgliosis and astrogliosis) have been observed in diseased regions, due to sustained cellular proliferation in response to disturbances, loss of homeostasis or the accumulation of Aβ<sup><xref ref-type="bibr" rid="c13">13</xref>, <xref ref-type="bibr" rid="c54">54</xref>, <xref ref-type="bibr" rid="c55">55</xref></sup>. Excessive proliferation leads to the transition of homeostatic microglia to its senescent or disease-associated type, also called DAM in mice models, via the processes mediated by <italic>TREM2-APOE</italic> signalling<sup><xref ref-type="bibr" rid="c54">54</xref>, <xref ref-type="bibr" rid="c56">56</xref>, <xref ref-type="bibr" rid="c57">57</xref></sup>. Increased number of dystrophic microglia, a form of cellular senescence characterized as beading and fragmentation of the branches of microglia, has been seen in multiple NDs such as AD, DLB and TDP-43 encephalopathy<sup><xref ref-type="bibr" rid="c58">58</xref></sup>. The presence of senescent microglia is believed to ultimately contribute to the failure of brain homeostasis and to clinical symptamology<sup><xref ref-type="bibr" rid="c57">57</xref>, <xref ref-type="bibr" rid="c59">59</xref>, <xref ref-type="bibr" rid="c60">60</xref></sup>.</p>
<p>Other non-neuronal cells such as oligodendrocytes and endothelial cells also associated with spatial tissue vulnerability to all NDs aside ALS (<xref rid="fig2" ref-type="fig">Figs. 2J, L</xref>). Oligodendrocytes are responsible for the synthesis and maintenance of myelin in the brain<sup><xref ref-type="bibr" rid="c61">61</xref></sup>. Demyelination produces loss of axonal insulation leading to sensory or motor neuron death in AD and ALS<sup><xref ref-type="bibr" rid="c61">61</xref>, <xref ref-type="bibr" rid="c62">62</xref></sup>. Oligodendrocytes were shown to be highly genetically associated with PD<sup><xref ref-type="bibr" rid="c63">63</xref>-<xref ref-type="bibr" rid="c65">65</xref></sup> and be particularly vulnerable to the alpha-synuclein accumulation<sup><xref ref-type="bibr" rid="c66">66</xref>, <xref ref-type="bibr" rid="c67">67</xref></sup> Mature oligodendrocytes may be in direct contact with the vascular basement membrane, allowing the direct signaling and exchange of substances with endothelial cells<sup><xref ref-type="bibr" rid="c68">68</xref>, <xref ref-type="bibr" rid="c69">69</xref></sup>. This particular location could underlie specific functions of vasculature-associated oligodendrocytes, which may contribute to the observed oligodendrocytes-mediated tissue vulnerability in NDs<sup><xref ref-type="bibr" rid="c68">68</xref></sup>. In addition, densities of OPCs showed strong correlations with the atrophy patterns of DLB and TDP43C. OPCs regulate neural activity and harbor immune-related and vascular-related functions<sup><xref ref-type="bibr" rid="c70">70</xref></sup>. In response to oligodendrocyte damage, OPCs initiate their proliferation and differentiation for the purpose of repairing damaged myelin<sup><xref ref-type="bibr" rid="c71">71</xref></sup>. In AD, PD and ALS, the OPCs become unable to differentiate and their numbers decrease, leading to a reduction in myelin production and subsequent neural damage<sup><xref ref-type="bibr" rid="c72">72</xref>, <xref ref-type="bibr" rid="c73">73</xref></sup>. Curiously, depletion of TDP-43 proteins (in TDP-43A&amp;C, FTD and ALS) may provoke the progressive loss of oligodendrocytes and OPCs<sup><xref ref-type="bibr" rid="c74">74</xref>, <xref ref-type="bibr" rid="c75">75</xref></sup>.</p>
<p>We observed (<xref rid="fig2" ref-type="fig">Fig. 2</xref>) that neuronal abundance distribution is also associated with tissue damage in many neurodegenerative conditions. However, these associations are less strong than for other cell-types, except for the ALS case (<xref rid="fig2" ref-type="fig">Fig. 2K</xref>). For this disorder, neuron proportions positively correlated with tissue integrity (i.e., the higher the neuronal proportion the less atrophy in a region). This observation suggests that increased neuronal presence at brain regions (relative to all considered cell-types) may have a protective effect in ALS, making neuronal enriched regions less vulnerable to damage in this disorder. In addition, we observed particularly weak associations between neuronal proportions and tissue damage in FTD and PD (<xref rid="fig2" ref-type="fig">Fig. 2L</xref>), suggesting that these disorders may be primary associated with supportive cell-types (astrocytes and oligodendrocytes, respectively; <xref rid="fig2" ref-type="fig">Figs. 2I, J</xref>).</p>
</sec>
<sec id="s2c">
<title>Spatial cell-types grouping exposes distinctive disease-disease mechanisms</title>
<p>Next, we hypothesized that diseases sharing similar biological mechanisms and clinical manifestations present common across-brain patterns of cell-types density associations. <xref rid="fig3" ref-type="fig">Figure 3</xref> shows a hierarchical taxonomy dendrogram grouping cell-types and diseases according to their common brain-wide correlation patterns. We observed that AD-related conditions formed its own cluster with other tau pathologies. Also, patterns of cell-types vs tissue loss in both PD and ALS (known for causing major motor symptoms) were distinct compared with the group of dementias, which primary affect cognitive functioning.</p>
<fig id="fig3" position="float" fig-type="figure">
<label>Figure 3.</label>
<caption><p>Cells and diseases similarities based on shared distributions. A) Dendrogram and unsupervised hierarchical clustering heatmap of Spearman’s correlations between cell-type proportions and atrophy patterns of the eleven neurodegenerative diseases. B) Cell-cell associations based on regional vulnerabilities to tissue loss across neurodegenerative conditions. C) Disease-disease similarities across cell-types. In A), red color corresponds to strong positive correlations between cells and diseases, white to no correlation, and dark blue to strong negative correlation.</p></caption>
<graphic xlink:href="544227v1_fig3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Patterns in cellular vulnerability in DLB did not strongly resemble PD without dementia (<xref rid="fig3" ref-type="fig">Fig. 3C</xref>), although both conditions involve alpha-synuclein aggregates<sup><xref ref-type="bibr" rid="c76">76</xref></sup>. This observation supports the hypothesis that clinical deterioration in DLB and PD is not uniquely caused by alpha-synuclein neurodegeneration alone but by distinctive regional spreading patterns<sup><xref ref-type="bibr" rid="c77">77</xref>, <xref ref-type="bibr" rid="c78">78</xref></sup>. Previously, differences in cell-type-specific gene expression and bulk-tissue samplesdifferential splicing distinguished PD from the Lewy body dementias, with PDD and DLB demonstrating more similarities<sup><xref ref-type="bibr" rid="c64">64</xref></sup>. Similar observation can be made for ALS and FTD, despite the presence of TDP-43 accumulations in both conditions<sup><xref ref-type="bibr" rid="c79">79</xref></sup> and their strong genetical overlap<sup><xref ref-type="bibr" rid="c80">80</xref></sup>, they did not group together and with FTLD-tau pathologies (3RTau, 4RTau, TDP43A) based on patterns of cellular vulnerabilities. These results emphasize the fundamental role of network topology (beyond the presence of toxic misfolded proteins) in developing characteristic tissue loss and clinical manifestations in NDs<sup><xref ref-type="bibr" rid="c33">33</xref>, <xref ref-type="bibr" rid="c81">81</xref>-<xref ref-type="bibr" rid="c83">83</xref></sup>.</p>
<p>Among all cell-types, neurons and OPCs spatial density distributions were least associated with tissue atrophy in all eleven disorders, subsequently clustering together. Astrocytes and microglia distributions showed the strongest associations with dementia-related pathologies, and thus formed a separate group while still being related with oligodendrocytes and endothelial cells. Astrocytes and microglia are known to be intimately related in the pathophysiological processes of NDs <sup><xref ref-type="bibr" rid="c13">13</xref></sup>. Both are key regulators of inflammatory responses in the central nervous system, and given their role in clearing misfolded proteins, dysfunctions of each of them can result in the accumulation of Aβ and tau<sup><xref ref-type="bibr" rid="c13">13</xref>, <xref ref-type="bibr" rid="c17">17</xref></sup>. During the progression of AD and PD, resident microglia undergo proinflammatory activation, resulting in an increased capacity to convert resting astrocytes to reactive astrocytes <sup><xref ref-type="bibr" rid="c84">84</xref></sup>. Recent studies demonstrated that blocking the microglial-mediated conversion of astrocytes to a neurotoxic reactive phenotype could limit neurodegeneration in AD and PD<sup><xref ref-type="bibr" rid="c84">84</xref>, <xref ref-type="bibr" rid="c85">85</xref></sup>.</p>
</sec>
</sec>
<sec id="s3">
<title>Discussion</title>
<p>Previous efforts to describe the composition of the brain’s different cell populations related to neurodegeneration have been limited to a few isolated regions. In the most systematic study of its kind, here we characterized large-scale spatial associations between canonical cell-types and brain tissue loss across all cortical and subcortical gray matter areas in eleven neurodegenerative disorders (including early- and late-AD, PD, FTD, DLB, ALS, tauopathies). Starting from gene expression and structural MRIs from the Allen Human Brain Atlas<sup><xref ref-type="bibr" rid="c39">39</xref></sup>, and extending our analysis with advanced RNAseq cells deconvolution approaches and whole-brain atrophy maps from clinically and/or neuropathologically confirmed diseases. We determined that (i) the spatial distributions of non-neuronal cell-types, primarily microglia and astrocytes, are strongly associated with the spread tissue damage present in many neurodegenerative disorders; (ii) cells and diseases define major axes that underlie spatial vulnerability according with shared cellular mechanisms, which aid in comprehending heterogeneity behind distinct and similar clinical manifestations/definitions; (iii) the generated whole-brain maps of cellular abundance can be similarly used for studying cellular processes in other neurological conditions (e.g., neurodevelopmental and neuropsychiatric disorders). Overall, our findings stress the critical need to surpass the current neuro-centric view of brain diseases and the imperative for identifying cell-specific therapeutic targets in neurodegeneration<sup><xref ref-type="bibr" rid="c59">59</xref></sup>. For further translation and validation, all resulting cells abundance maps and analytic tools are freely shared with the community.</p>
<p>We derived, first to our knowledge, high resolution maps of cellular abundance/proportion in the adult human brain for six canonical cell-types, including astrocytes, neurons, oligodendrocytes, microglia, and endothelial cells. As mentioned, previous cellular analyses of neurological conditions have been restricted to expert-selected isolated brain areas. The invasive nature of expression assays, requiring direct access to neural tissue, and other numerous scaling limitations have impeded extensive spatial analyses<sup><xref ref-type="bibr" rid="c86">86</xref></sup>. Earlier studies, also using AHBA data, have shown that spatial patterns in gene expression and cell-type-specific genetic markers are associated with both regional vulnerability to neurodegeneration and patterns of atrophy across the brain<sup><xref ref-type="bibr" rid="c7">7</xref>, <xref ref-type="bibr" rid="c23">23</xref>-<xref ref-type="bibr" rid="c26">26</xref></sup>. Since many neurodegeneration-related genes have similar levels of expression in both affected and unaffected brain areas<sup><xref ref-type="bibr" rid="c87">87</xref></sup>, characterizing changes in tissue loss associated with cell-type proportions may provide a clearer perspective on large-scale spatial patterns of cellular vulnerability. Our maps of cells-abundance are available for the scientific and clinical community, potentially allowing researchers to further study spatial variations in cell-types density with macroscale phenotypes. These maps can be used in future studies concerning brain structure and function in both health and disease. They can be also explored in context of other neurological diseases including neurodevelopmental and psychiatric conditions.</p>
<p>Our results demonstrate that all canonical cell-types express vulnerability to dementia-related atrophy of brain tissue, suggesting the disruption of the molecular pathways involving specific cell-types can contribute to their observed dysfunctions and subsequent clinical symptamology<sup><xref ref-type="bibr" rid="c59">59</xref></sup>. Previously, transcriptional profiling of prefrontal cortex in AD showed reduced proportions of neurons, astrocytes, oligodendrocytes, and homeostatic microglia<sup><xref ref-type="bibr" rid="c88">88</xref></sup>. In contrast, bulk-RNA analysis of diseased AD tissues from various human brain regions observed neuronal loss and increased cell abundance of microglia, astrocytes, and oligodendrocytes<sup><xref ref-type="bibr" rid="c89">89</xref>, <xref ref-type="bibr" rid="c90">90</xref></sup>. Furthermore, increased microglial, endothelial cells, and oligodendrocytes population was observed in PD and other Lewy diseases<sup><xref ref-type="bibr" rid="c64">64</xref>, <xref ref-type="bibr" rid="c91">91</xref></sup>. Cortical regions exhibiting the most severe atrophy in FTD showed increased gene expression of astrocytes and endothelial cells<sup><xref ref-type="bibr" rid="c26">26</xref></sup>. In line with these results, we observed that regions with increased cell-type proportions, particularly for astrocytes and microglia, are more vulnerable to tissue atrophy in almost all neurodegenerative conditions. This may partly explain the reported cellular proliferation through microglial activation in diseased regions in response to the misfolded protein accumulation or other pathobiological processes<sup><xref ref-type="bibr" rid="c54">54</xref>, <xref ref-type="bibr" rid="c60">60</xref></sup>. As disease progresses, the release of inflammatory agents by sustained microglial activation is believed to be responsible for exacerbating neurodegeneration and clinical symptoms<sup><xref ref-type="bibr" rid="c18">18</xref>, <xref ref-type="bibr" rid="c21">21</xref></sup>. Microglial activation in pair with gray matter atrophy in frontal cortex were shown to be directly associated with cognitive decline in FTD<sup><xref ref-type="bibr" rid="c52">52</xref></sup>.</p>
<p>Taken together, our findings support genome-wide association and transcriptional studies suggesting that cell-type-specific alterations in NDs may indicate the disruption of the following distinct and overlapping molecular pathways: inflammation, immune response, and homeostasis (astrocytes and microglia), vascular system (endothelial cells), and myelination (oligodendrocytes and OPCs)<sup><xref ref-type="bibr" rid="c88">88</xref>, <xref ref-type="bibr" rid="c92">92</xref>-<xref ref-type="bibr" rid="c94">94</xref></sup>. Recent study identified a degree of similarities (grouping) in cell-type expression between AD, FTD, and ALS, distinguishing them from other neurological disorders<sup><xref ref-type="bibr" rid="c7">7</xref></sup>. Interestingly, our results showed all dementia conditions were similar in their patterns of cell-types associations with tissue loss relative to PD and ALS. AD-associated changes in cell-types proportions were previously suggested to be related to the presence of dementia, not to plaques and tangles<sup><xref ref-type="bibr" rid="c95">95</xref></sup>. There were no strong similarities in patterns of vulnerabilities between pairs of conditions (PD without dementia and DLB, FTD and ALS) with associated genetic risks and type of toxic proteins<sup><xref ref-type="bibr" rid="c76">76</xref>, <xref ref-type="bibr" rid="c79">79</xref>, <xref ref-type="bibr" rid="c80">80</xref></sup>. These results reinforce our statement on gray matter atrophy patterns in NDs being not uniquely provoked by genes and misfolded proteins toxicity alone but affected and mediated by additional factors such as metabolic and vascular dysregulations<sup><xref ref-type="bibr" rid="c81">81</xref>, <xref ref-type="bibr" rid="c96">96</xref>-<xref ref-type="bibr" rid="c98">98</xref></sup>.</p>
<p>Our study also has a number of limitations. First, our analyses were focused on stereotypic atrophy patterns for each disorder. It is known that NDs are highly heterogenous, with molecular, phenotypic, and clinical subtypes potentially varying in atrophy patterns<sup><xref ref-type="bibr" rid="c99">99</xref>, <xref ref-type="bibr" rid="c100">100</xref></sup>. Further investigation of cell-type signatures across various subtypes and disease stages may better characterize each case. Similarly, it has been observed that cell-type-related transcriptional changes are different between sexes<sup><xref ref-type="bibr" rid="c70">70</xref></sup>, making future sex-specific analyses indispensable for further understanding of sex-related pathomechanisms. Examined atrophy maps were coming from different studies (Table S2), with differences in data acquisition protocols (e.g., spatial resolution) and technical procedures (e.g., smoothing level, statistical methods). In complementary analyses, we observed almost identical results after smoothing all disease-specific images with the same kernel size, while they were already mapped at the same spatial resolution for this study and statistically adjusted by acquisition parameters (e.g., field strength) in original studies. Cell-types deconvolution approaches are varied and limited in their precision<sup><xref ref-type="bibr" rid="c101">101</xref></sup>. Here, we used a previously validated deconvolution method designed for efficiently estimating cell proportions for six major cell-types from bulk mRNA expression <sup><xref ref-type="bibr" rid="c41">41</xref></sup>. Conveniently, this method is freely available for researchers (R package, BRETIGEA), which will facilitate reproducibility analyses of our study. Other important considerations are the dynamic nature of gene expression as disease progresses<sup><xref ref-type="bibr" rid="c102">102</xref>, <xref ref-type="bibr" rid="c103">103</xref></sup>, <italic>post-mortem</italic> RNA degradation of the used templates <sup><xref ref-type="bibr" rid="c104">104</xref></sup>, and the subsequent limited ability of bulk RNA sequencing to reflect cell-to-cell variability, which is relevant for understanding cell heterogeneity and the roles of specific cell populations in disease <sup><xref ref-type="bibr" rid="c105">105</xref></sup>. Lastly, a promising future direction would be to validate our findings with single-cell spatial analyses alongside cellular interaction modeling with pluripotent stem (iPS) cells.</p>
</sec>
<sec id="s4">
<title>Materials and Methods</title>
<sec id="s4a">
<title>Disease-specific atrophy maps</title>
<p>Voxel-wise brain atrophy maps in early- and late-onset Alzheimer’s disease (EOAD and LOAD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), dementia with Lewy bodies (DLB) and dementia-related pathologies (presenilin-1, TDP43A, TDP43C, 3RTau, and 4RTau) were adopted from open data repositories and/or requested from collaborators<sup><xref ref-type="bibr" rid="c32">32</xref>, <xref ref-type="bibr" rid="c33">33</xref></sup>, as specified below. Reduction in gray matter (GM) density in diseased atrophy maps relative to controls was measured by voxel- and deformation-based morphometry (VBM and DBM) applied to structural T1-weighted MR images, and thus were expressed as t-score per voxel (relatively low negative t-scores indicate greater GM tissue loss/atrophy)<sup><xref ref-type="bibr" rid="c36">36</xref>, <xref ref-type="bibr" rid="c37">37</xref></sup>. VBM is a hypothesis-free technique for analyzing neuroimaging data that characterizes regional tissue concentration differences across the whole brain, without the need to predefine regions of interest<sup><xref ref-type="bibr" rid="c106">106</xref></sup>. DBM is a similar widely used technique to identify structural changes in the brain across participants, which in addition considers anatomical differences such as shape and size of brain structures<sup><xref ref-type="bibr" rid="c107">107</xref></sup>. See Table S2 for study-origin, sample size and imaging technique corresponding to each atrophy map.</p>
<p>MRI data for neuropathological dementias were collected from 186 individuals and averaged across participants per condition: 107 had a primary AD diagnosis (68 early-onset (&lt;65 years at disease onset), 29 late onset (≥65 years at disease onset), 10 presenilin-1 mutation carriers), 25 with DLB, 11 with 3-repeat-tau, 17 with 4-repeat-tau, 12 TDP43A, and 14 TDP43C)<sup><xref ref-type="bibr" rid="c32">32</xref></sup>. Data were collected from multiple centres on scanners from three different manufacturers (Philips, GE, Siemens), using a variety of different imaging protocols<sup><xref ref-type="bibr" rid="c32">32</xref></sup>. Magnetic field strength varied between 1.0 T (n=15 scans), 1.5 T (n=201 scans) and 3 T (n=43 scans)<sup><xref ref-type="bibr" rid="c32">32</xref></sup>. Atrophy maps were statistically adjusted for age, sex, total intracranial volume, and MRI strength field and site<sup><xref ref-type="bibr" rid="c32">32</xref></sup>. Ethical approval for this retrospective study was obtained from the National Research Ethics Service Committee London-Southeast<sup><xref ref-type="bibr" rid="c32">32</xref></sup>.</p>
<p>MRI data for PD, consisted of 3T high-resolution T1-weighted scans, were obtained from the Parkinson’s Progression Markers Initiative (PPMI) database (<ext-link ext-link-type="uri" xlink:href="http://www.ppmiinfo.org/data">www.ppmiinfo.org/data</ext-link>). The PPMI is a multi-center international study with approved protocols by the local institutional review boards at all 24 sites across the US, Europe, and Australia<sup><xref ref-type="bibr" rid="c83">83</xref></sup>. MRI and clinical data used in constructing atrophy maps were collected from 232 participants with PD<sup><xref ref-type="bibr" rid="c83">83</xref></sup>. PD subjects (77 females; age 61.2 ± 9.1) were required to be at least 30 years old or older, untreated with PD medications within 2 years of diagnosis, and to display at least two or more PD-related motor symptoms<sup><xref ref-type="bibr" rid="c83">83</xref></sup>. No significant effect of age, gender, or site was found<sup><xref ref-type="bibr" rid="c83">83</xref></sup>.</p>
<p>For ALS, MRI data was collected from 66 patients (24 females; age 57.98 ± 10.84) with both sporadic or familial form of disease from centers of the Canadian ALS Neuroimaging Consortium (<ext-link ext-link-type="uri" xlink:href="http://calsnic.org/">http://calsnic.org/</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> NCT02405182), which included 3T MRI sites in University of Alberta, University of Calgary, University of Toronto, and McGill University<sup><xref ref-type="bibr" rid="c108">108</xref></sup>. All participants gave written informed consent, and the study was approved by the health research ethics boards at each of the participating sites<sup><xref ref-type="bibr" rid="c108">108</xref></sup>. Participants were excluded if they had a history of other neurological or psychiatric disorders, prior brain injury or respiratory impairment resulting in an inability to tolerate the MRI protocol<sup><xref ref-type="bibr" rid="c108">108</xref></sup>. Normative aging as well as sex differences were regressed out from data prior the map construction<sup><xref ref-type="bibr" rid="c108">108</xref></sup>.</p>
<p>For FTD, MRI data was accessed from the frontotemporal lobar degeneration neuroimaging initiative (FTLDNI), which included 125 patients (73 females, age 63.52 ± 7.03) with frontotemporal dementia diagnosis<sup><xref ref-type="bibr" rid="c109">109</xref></sup>. 3T structural images were collected on three following sites: University of California San Francisco, Mayo Clinic, and Massachusetts General Hospital<sup><xref ref-type="bibr" rid="c109">109</xref></sup>. All subjects provided informed consent and the protocol was approved by the institution review board at all sites<sup><xref ref-type="bibr" rid="c109">109</xref></sup>. For up-to-date information on participation and protocol, please visit: <ext-link ext-link-type="uri" xlink:href="http://memory.ucsf.edu/research/studies/nifd">http://memory.ucsf.edu/research/studies/nifd</ext-link>.</p>
</sec>
<sec id="s4b">
<title>Mapping gene expression data</title>
<p>To construct a comprehensive transcriptome atlas, we used RNA microarray gene expression data from the Allen Human Brain Atlas (AHBA; <ext-link ext-link-type="uri" xlink:href="https://human.brain-map.org/">https://human.brain-map.org/</ext-link>)<sup><xref ref-type="bibr" rid="c39">39</xref></sup>. The AHBA included anatomical and histological data collected from six healthy human specimens with no known neurological disease history (one female; age range 24–57 years; mean age 42.5 ± 13.38 years)<sup><xref ref-type="bibr" rid="c39">39</xref></sup>. Two specimens contained data from the entire brain, whereas the remaining four included data from the left hemisphere only, with 3702 spatially distinct samples in total<sup><xref ref-type="bibr" rid="c39">39</xref></sup>. The samples were distributed across cortical, subcortical, brainstem and cerebellar regions in each brain, and quantified the expression levels of more than 20,000 genes<sup><xref ref-type="bibr" rid="c39">39</xref></sup>. mRNA data for specific brain locations were accompanied by structural MR data from each individual and were labeled with Talairach native coordinates and Montreal Neurological Institute (MNI) coordinates, which allowed us to match samples to imaging data.</p>
<p>Following the validated approach in <sup><xref ref-type="bibr" rid="c40">40</xref></sup>, missing data points between samples for each MNI coordinate were interpolated using Gaussian-process regression, a widely used method for data interpolation in geostatistics. MNI coordinates for missing mRNA values were taken from the GM regions of the AAL atlas. Spatial covariance between coordinates from 3072 AHBA tissue samples and coordinates from the AAL atlas was estimated via the quadratic exponential kernel function. mRNA expression at each MNI coordinate was then predicted by multiplying AHBA gene express values that corresponded to specific probes to kernel covariance matrix divided by the sum of kernels.</p>
</sec>
<sec id="s4c">
<title>Cell-type proportion estimation</title>
<p>Densities for multiple canonical cell-types were estimated at the gray matter (GM) by applying an R-package Brain Cell-type Specific Gene Expression Analysis (BRETIGEA), with known genetic markers to the transcriptome atlas<sup><xref ref-type="bibr" rid="c41">41</xref></sup>. This deconvolution method was designed for estimating cell proportions in bulk mRNA expression data for six major cell-types: neurons, astrocytes, oligodendrocytes, microglia, endothelial cells, and oligodendrocyte precursor cells<sup><xref ref-type="bibr" rid="c41">41</xref></sup>. We chose 15 representative gene markers per each cell-type (90 in total) from the BRETIGEA human brain marker gene set and then selected those genes that were also present in the AHBA gene expression database with matching gene probes. This resulted in eighty cell-type-related gene markers that were used in missing data interpolation and the deconvolution and proportion estimation analysis (Table S3). For each voxel, each cell-type proportion value was normalized relative to the sum of all six cell-types and the sum was scaled relative to the gray matter density. We then registered data into MNI and volumetric space using the ICBM152 template<sup><xref ref-type="bibr" rid="c38">38</xref></sup>.</p>
<p>For the correlation analysis, cell densities were averaged over 118 anatomical regions in gray matter defined by the extended automated anatomical labelling atlas (AAL; Table S1)<sup><xref ref-type="bibr" rid="c42">42</xref></sup>. We repeated the correlation analysis for the 98 regions from the Desikan-Killiany-Tourville atlas (DKT; Fig. S1)<sup><xref ref-type="bibr" rid="c43">43</xref></sup>.</p>
</sec>
</sec>
<sec id="d1e1215" sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material id="d1e1324">
<label>Supplementary information</label>
<media xlink:href="supplements/544227_file06.docx"/>
</supplementary-material>
</sec>
</body>
<back>
<sec id="s5">
<title>Data analysis</title>
<p>We constructed a 6□×□11 correlation matrix by computing inter-regional Spearman’s correlations between spatial distributions of the six canonical cell-types and patterns of atrophy in eleven neurodegenerative conditions. Shapiro-Wilk tests were used to examine the normality of data distribution. Hierarchical clustering analyses was applied using in-built MATLAB function for data visualization. Samples were clustered together based on estimated averaged linkage Euclidian distance between them.</p>
</sec>
<sec id="s6">
<title>Data and materials availability</title>
<p>All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. The BRETIGEA R package can be downloaded from <ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/package=BRETIGEA">https://cran.r-project.org/package=BRETIGEA</ext-link>. The Allen Human Brain Atlas data is available at <ext-link ext-link-type="uri" xlink:href="https://human.brain-map.org/static/download">https://human.brain-map.org/static/download</ext-link>. Atrophy maps for pathologically confirmed dementia are available at <ext-link ext-link-type="uri" xlink:href="http://neurovault.org/collections/ADHMHOPN/">http://neurovault.org/collections/ADHMHOPN/</ext-link>. Raw demographic and MRI data from PD and ALS patients can be accessed at <ext-link ext-link-type="uri" xlink:href="http://www.ppmiinfo.org/data">www.ppmiinfo.org/data</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://calsnic.org/">http://calsnic.org/</ext-link> (<ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> NCT02405182), respectively. We anticipate that resulting cells abundance maps will be freely shared with the community with article publication (at our lab’s GitHub space <ext-link ext-link-type="uri" xlink:href="https://github.com/neuropm-lab">https://github.com/neuropm-lab</ext-link>).</p>
</sec>
<ack>
<title>Acknowledgments</title>
<p>This project was undertaken thanks in part to the following funding awards to YIM: the Canada Research Chair tier 2, the CIHR Project Grant 2020, the Weston Family Foundation’s Transformational Research in AD 2020, and the New Investigator start-up grant from McGill University’s <italic>Healthy Brains for Healthy Lives Initiative</italic> (HBHL, <italic>Canada First Research Excellence Fund</italic>). First author VP was partly supported by HBHL’s Theme 1 Discovery fund 2022-2025. In addition, we used the computational infrastructure of the McConnell Brain Imaging Center at the Montreal Neurological Institute, supported in part by the <italic>Brain Canada Foundation</italic>, through the <italic>Canada Brain Research Fund</italic>, with the financial support of <italic>Health Canada</italic> and sponsors.</p>
</ack>
<sec id="s7">
<title>Competing interests</title>
<p>The authors declare no competing interest.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><string-name><surname>Gorman</surname> <given-names>AM</given-names></string-name>. <article-title>Neuronal cell death in neurodegenerative diseases: recurring themes around protein handling</article-title>. <source>J Cell Mol Med</source> <year>2008</year>;<volume>12</volume>:<fpage>2263</fpage>–<lpage>2280</lpage>.</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><string-name><surname>Duong</surname> <given-names>S</given-names></string-name>, <string-name><surname>Patel</surname> <given-names>T</given-names></string-name>, <string-name><surname>Chang</surname> <given-names>F.</given-names></string-name> <article-title>Dementia: What pharmacists need to know</article-title>. <source>Can Pharm J (Ott)</source> <year>2017</year>;<volume>150</volume>:<fpage>118</fpage>–<lpage>129</lpage>.</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><string-name><surname>Bosco</surname> <given-names>DA</given-names></string-name>, <string-name><surname>LaVoie</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Petsko</surname> <given-names>GA</given-names></string-name>, <string-name><surname>Ringe</surname> <given-names>D.</given-names></string-name> <article-title>Proteostasis and movement disorders: Parkinson’s disease and amyotrophic lateral sclerosis</article-title>. <source>Cold Spring Harb Perspect Biol</source> <year>2011</year>;<volume>3</volume>:<fpage>a007500</fpage>.</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><string-name><surname>Wingo</surname> <given-names>TS</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Gerasimov</surname> <given-names>ES</given-names></string-name>, <etal>et al.</etal> <article-title>Shared mechanisms across the major psychiatric and neurodegenerative diseases</article-title>. <source>Nat Commun</source> <year>2022</year>;<volume>13</volume>:<fpage>4314</fpage>.</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="other"><string-name><surname>Huseby</surname> <given-names>CJ</given-names></string-name>, <string-name><surname>Delvaux</surname> <given-names>E</given-names></string-name>, <string-name><surname>Brokaw</surname> <given-names>DL</given-names></string-name>, <string-name><surname>Coleman</surname> <given-names>PD</given-names></string-name>. <article-title>Blood RNA transcripts reveal similar and differential alterations in fundamental cellular processes in Alzheimer’s disease and other neurodegenerative diseases</article-title>. <source>Alzheimers Dement</source> <year>2022</year>.</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><string-name><surname>Arneson</surname> <given-names>D</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Narayanan</surname> <given-names>M.</given-names></string-name> <article-title>Shared mechanisms among neurodegenerative diseases: from genetic factors to gene networks</article-title>. <source>J Genet</source> <year>2018</year>;<volume>97</volume>:<fpage>795</fpage>–<lpage>806</lpage>.</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><string-name><surname>Zeighami</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Bakken</surname> <given-names>TE</given-names></string-name>, <string-name><surname>Nickl-Jockschat</surname> <given-names>T</given-names></string-name>, <etal>et al.</etal> <article-title>A comparison of anatomic and cellular transcriptome structures across 40 human brain diseases</article-title>. <source>PLoS Biol</source> <year>2023</year>;<volume>21</volume>:<fpage>e3002058</fpage>.</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><string-name><surname>Bordone</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Barbosa-Morais</surname> <given-names>NL</given-names></string-name>. <article-title>Unraveling Targetable Systemic and Cell-Type-Specific Molecular Phenotypes of Alzheimer’s and Parkinson’s Brains With Digital Cytometry</article-title>. <source>Front Neurosci</source> <year>2020</year>;<volume>14</volume>:<fpage>607215</fpage>.</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><string-name><surname>Lee</surname> <given-names>H</given-names></string-name>, <string-name><surname>Fenster</surname> <given-names>RJ</given-names></string-name>, <string-name><surname>Pineda</surname> <given-names>SS</given-names></string-name>, <etal>et al.</etal> <article-title>Cell Type-Specific Transcriptomics Reveals that Mutant Huntingtin Leads to Mitochondrial RNA Release and Neuronal Innate Immune Activation</article-title>. <source>Neuron</source> <year>2020</year>;<volume>107</volume>:<fpage>891</fpage>–<lpage>908 e898</lpage>.</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><string-name><surname>Reynolds</surname> <given-names>RH</given-names></string-name>, <string-name><surname>Botia</surname> <given-names>J</given-names></string-name>, <string-name><surname>Nalls</surname> <given-names>MA</given-names></string-name>, <etal>et al.</etal> <article-title>Moving beyond neurons: the role of cell type-specific gene regulation in Parkinson’s disease heritability</article-title>. <source>NPJ Parkinsons Dis</source> <year>2019</year>;<volume>5</volume>:<fpage>6</fpage>.</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><string-name><surname>Wareham</surname> <given-names>LK</given-names></string-name>, <string-name><surname>Liddelow</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Temple</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal> <article-title>Solving neurodegeneration: common mechanisms and strategies for new treatments</article-title>. <source>Mol Neurodegener</source> <year>2022</year>;<volume>17</volume>:<fpage>23</fpage>.</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><string-name><surname>Guzman-Martinez</surname> <given-names>L</given-names></string-name>, <string-name><surname>Maccioni</surname> <given-names>RB</given-names></string-name>, <string-name><surname>Andrade</surname> <given-names>V</given-names></string-name>, <string-name><surname>Navarrete</surname> <given-names>LP</given-names></string-name>, <string-name><surname>Pastor</surname> <given-names>MG</given-names></string-name>, <string-name><surname>Ramos-Escobar</surname> <given-names>N.</given-names></string-name> <article-title>Neuroinflammation as a Common Feature of Neurodegenerative Disorders</article-title>. <source>Front Pharmacol</source> <year>2019</year>;<volume>10</volume>:<fpage>1008</fpage>.</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><string-name><surname>Kwon</surname> <given-names>HS</given-names></string-name>, <string-name><surname>Koh</surname> <given-names>SH</given-names></string-name>. <article-title>Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes</article-title>. <source>Transl Neurodegener</source> <year>2020</year>;<volume>9</volume>:<fpage>42</fpage>.</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><string-name><surname>Kalaria</surname> <given-names>RN</given-names></string-name>. <article-title>The blood-brain barrier and cerebrovascular pathology in Alzheimer’s disease</article-title>. <source>Ann N Y Acad Sci</source> <year>1999</year>;<volume>893</volume>:<fpage>113</fpage>–<lpage>125</lpage>.</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><string-name><surname>Chen</surname> <given-names>X</given-names></string-name>, <string-name><surname>Guo</surname> <given-names>C</given-names></string-name>, <string-name><surname>Kong</surname> <given-names>J.</given-names></string-name> <article-title>Oxidative stress in neurodegenerative diseases</article-title>. <source>Neural Regen Res</source> <year>2012</year>;<volume>7</volume>:<fpage>376</fpage>–<lpage>385</lpage>.</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><string-name><surname>Kinney</surname> <given-names>JW</given-names></string-name>, <string-name><surname>Bemiller</surname> <given-names>SM</given-names></string-name>, <string-name><surname>Murtishaw</surname> <given-names>AS</given-names></string-name>, <string-name><surname>Leisgang</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Salazar</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Lamb</surname> <given-names>BT</given-names></string-name>. <article-title>Inflammation as a central mechanism in Alzheimer’s disease</article-title>. <source>Alzheimers Dement (N Y)</source> <year>2018</year>;<volume>4</volume>:<fpage>575</fpage>–<lpage>590</lpage>.</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><string-name><surname>Leyns</surname> <given-names>CEG</given-names></string-name>, <string-name><surname>Holtzman</surname> <given-names>DM</given-names></string-name>. <article-title>Glial contributions to neurodegeneration in tauopathies</article-title>. <source>Mol Neurodegener</source> <year>2017</year>;<volume>12</volume>:<fpage>50</fpage>.</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><string-name><surname>Maccioni</surname> <given-names>RB</given-names></string-name>, <string-name><surname>Rojo</surname> <given-names>LE</given-names></string-name>, <string-name><surname>Fernández</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Kuljis</surname> <given-names>RO</given-names></string-name>. <article-title>The role of neuroimmunomodulation in Alzheimer’s disease</article-title>. <source>Ann N Y Acad Sci</source> <year>2009</year>;<volume>1153</volume>:<fpage>240</fpage>–<lpage>246</lpage>.</mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><string-name><surname>Zang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>S</given-names></string-name>, <string-name><surname>Zhu</surname> <given-names>J</given-names></string-name>, <string-name><surname>Ma</surname> <given-names>J</given-names></string-name>, <string-name><surname>Zhai</surname> <given-names>Y.</given-names></string-name> <article-title>The Emerging Role of Central and Peripheral Immune Systems in Neurodegenerative Diseases</article-title>. <source>Front Aging Neurosci</source> <year>2022</year>;<volume>14</volume>:<fpage>872134</fpage>.</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><string-name><surname>Sochocka</surname> <given-names>M</given-names></string-name>, <string-name><surname>Donskow-Łysoniewska</surname> <given-names>K</given-names></string-name>, <string-name><surname>Diniz</surname> <given-names>BS</given-names></string-name>, <string-name><surname>Kurpas</surname> <given-names>D</given-names></string-name>, <string-name><surname>Brzozowska</surname> <given-names>E</given-names></string-name>, <string-name><surname>Leszek</surname> <given-names>J.</given-names></string-name> <article-title>The Gut Microbiome Alterations and Inflammation-Driven Pathogenesis of Alzheimer’s Disease-a Critical Review</article-title>. <source>Mol Neurobiol</source> <year>2019</year>;<volume>56</volume>:<fpage>1841</fpage>–<lpage>1851</lpage>.</mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><string-name><surname>Kempuraj</surname> <given-names>D</given-names></string-name>, <string-name><surname>Thangavel</surname> <given-names>R</given-names></string-name>, <string-name><surname>Natteru</surname> <given-names>PA</given-names></string-name>, <etal>et al.</etal> <article-title>Neuroinflammation Induces Neurodegeneration</article-title>. <source>J Neurol Neurosurg Spine</source> <year>2016</year>;<volume>1</volume>.</mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><string-name><surname>Castellani</surname> <given-names>G</given-names></string-name>, <string-name><surname>Croese</surname> <given-names>T</given-names></string-name>, <string-name><surname>Peralta Ramos</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Schwartz</surname> <given-names>M.</given-names></string-name> <article-title>Transforming the understanding of brain immunity</article-title>. <source>Science</source> <year>2023</year>;<volume>380</volume>:<fpage>eabo7649</fpage>.</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><string-name><surname>Vidal-Pineiro</surname> <given-names>D</given-names></string-name>, <string-name><surname>Parker</surname> <given-names>N</given-names></string-name>, <string-name><surname>Shin</surname> <given-names>J</given-names></string-name>, <etal>et al.</etal> <article-title>Cellular correlates of cortical thinning throughout the lifespan</article-title>. <source>Sci Rep</source> <year>2020</year>;<volume>10</volume>:<fpage>21803</fpage>.</mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><string-name><surname>Roshchupkin</surname> <given-names>GV</given-names></string-name>, <string-name><surname>Adams</surname> <given-names>HH</given-names></string-name>, <string-name><surname>van der Lee</surname> <given-names>SJ</given-names></string-name>, <etal>et al.</etal> <article-title>Fine-mapping the effects of Alzheimer’s disease risk loci on brain morphology</article-title>. <source>Neurobiol Aging</source> <year>2016</year>;<volume>48</volume>:<fpage>204</fpage>–<lpage>211</lpage>.</mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><string-name><surname>Zheng</surname> <given-names>YQ</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Yau</surname> <given-names>Y</given-names></string-name>, <etal>et al.</etal> <article-title>Local vulnerability and global connectivity jointly shape neurodegenerative disease propagation</article-title>. <source>PLoS Biol</source> <year>2019</year>;<volume>17</volume>:<fpage>e3000495</fpage>.</mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><string-name><surname>Altmann</surname> <given-names>A</given-names></string-name>, <string-name><surname>Cash</surname> <given-names>DM</given-names></string-name>, <string-name><surname>Bocchetta</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title>Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia</article-title>. <source>Brain Commun</source> <year>2020</year>;<volume>2</volume>.</mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><string-name><given-names>Cuevas-Diaz</given-names> <surname>Duran R</surname></string-name>, <string-name><surname>González-Orozco</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Velasco</surname> <given-names>I</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>JQ</given-names></string-name>. <article-title>Single-cell and single-nuclei RNA sequencing as powerful tools to decipher cellular heterogeneity and dysregulation in neurodegenerative diseases</article-title>. <source>Front Cell Dev Biol</source> <year>2022</year>;<volume>10</volume>:<fpage>884748</fpage>.</mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><string-name><surname>Luquez</surname> <given-names>T</given-names></string-name>, <string-name><surname>Gaur</surname> <given-names>P</given-names></string-name>, <string-name><surname>Kosater</surname> <given-names>IM</given-names></string-name>, <etal>et al.</etal> <article-title>Cell type-specific changes identified by single-cell transcriptomics in Alzheimer’s disease</article-title>. <source>Genome Med</source> <year>2022</year>;<volume>14</volume>:<fpage>136</fpage>.</mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><string-name><surname>Riley</surname> <given-names>BE</given-names></string-name>, <string-name><surname>Gardai</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>Emig-Agius</surname> <given-names>D</given-names></string-name>, <etal>et al.</etal> <article-title>Systems-based analyses of brain regions functionally impacted in Parkinson’s disease reveals underlying causal mechanisms</article-title>. <source>PLoS One</source> <year>2014</year>;<volume>9</volume>:<fpage>e102909</fpage>.</mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><string-name><surname>Arnatkeviciute</surname> <given-names>A</given-names></string-name>, <string-name><surname>Fulcher</surname> <given-names>BD</given-names></string-name>, <string-name><surname>Bellgrove</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Fornito</surname> <given-names>A.</given-names></string-name> <article-title>Imaging Transcriptomics of Brain Disorders</article-title>. <source>Biol Psychiatry Glob Open Sci</source> <year>2022</year>;<volume>2</volume>:<fpage>319</fpage>–<lpage>331</lpage>.</mixed-citation></ref>
<ref id="c31"><label>31.</label><mixed-citation publication-type="journal"><string-name><surname>Mrdjen</surname> <given-names>D</given-names></string-name>, <string-name><surname>Fox</surname> <given-names>EJ</given-names></string-name>, <string-name><surname>Bukhari</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Montine</surname> <given-names>KS</given-names></string-name>, <string-name><surname>Bendall</surname> <given-names>SC</given-names></string-name>, <string-name><surname>Montine</surname> <given-names>TJ</given-names></string-name>. <article-title>The basis of cellular and regional vulnerability in Alzheimer’s disease</article-title>. <source>Acta Neuropathol</source> <year>2019</year>;<volume>138</volume>:<fpage>729</fpage>–<lpage>749</lpage>.</mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><string-name><surname>Harper</surname> <given-names>L</given-names></string-name>, <string-name><surname>Bouwman</surname> <given-names>F</given-names></string-name>, <string-name><surname>Burton</surname> <given-names>EJ</given-names></string-name>, <etal>et al.</etal> <article-title>Patterns of atrophy in pathologically confirmed dementias: a voxelwise analysis</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <year>2017</year>;<volume>88</volume>:<fpage>908</fpage>–<lpage>916</lpage>.</mixed-citation></ref>
<ref id="c33"><label>33.</label><mixed-citation publication-type="journal"><string-name><surname>Zeighami</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Fereshtehnejad</surname> <given-names>SM</given-names></string-name>, <string-name><surname>Dadar</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title>A clinical-anatomical signature of Parkinson’s disease identified with partial least squares and magnetic resonance imaging</article-title>. <source>Neuroimage</source> <year>2019</year>;<volume>190</volume>:<fpage>69</fpage>–<lpage>78</lpage>.</mixed-citation></ref>
<ref id="c34"><label>34.</label><mixed-citation publication-type="journal"><collab>Parkinson Progression Marker I</collab>. <article-title>The Parkinson Progression Marker Initiative (PPMI)</article-title>. <source>Prog Neurobiol</source> <year>2011</year>;<volume>95</volume>:<fpage>629</fpage>–<lpage>635</lpage>.</mixed-citation></ref>
<ref id="c35"><label>35.</label><mixed-citation publication-type="other"><string-name><surname>Kalra</surname> <given-names>S</given-names></string-name>, <string-name><surname>Khan</surname> <given-names>M</given-names></string-name>, <string-name><surname>Barlow</surname> <given-names>L</given-names></string-name>, <etal>et al.</etal> <article-title>The Canadian ALS Neuroimaging Consortium (CALSNIC) - a multicentre platform for standardized imaging and clinical studies in ALS</article-title>. <source>medRxiv</source>, <year>2020</year>.</mixed-citation></ref>
<ref id="c36"><label>36.</label><mixed-citation publication-type="journal"><string-name><surname>Aubert-Broche</surname> <given-names>B</given-names></string-name>, <string-name><surname>Fonov</surname> <given-names>VS</given-names></string-name>, <string-name><surname>Garcia-Lorenzo</surname> <given-names>D</given-names></string-name>, <etal>et al.</etal> <article-title>A new method for structural volume analysis of longitudinal brain MRI data and its application in studying the growth trajectories of anatomical brain structures in childhood</article-title>. <source>Neuroimage</source> <year>2013</year>;<volume>82</volume>:<fpage>393</fpage>–<lpage>402</lpage>.</mixed-citation></ref>
<ref id="c37"><label>37.</label><mixed-citation publication-type="journal"><string-name><surname>Ashburner</surname> <given-names>J</given-names></string-name>, <string-name><surname>Friston</surname> <given-names>KJ</given-names></string-name>. <article-title>Voxel-based morphometry--the methods</article-title>. <source>Neuroimage</source> <year>2000</year>;<volume>11</volume>:<fpage>805</fpage>–<lpage>821</lpage>.</mixed-citation></ref>
<ref id="c38"><label>38.</label><mixed-citation publication-type="journal"><string-name><surname>Fonov</surname> <given-names>V</given-names></string-name>, <string-name><surname>Evans</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Botteron</surname> <given-names>K</given-names></string-name>, <string-name><surname>Almli</surname> <given-names>CR</given-names></string-name>, <string-name><surname>McKinstry</surname> <given-names>RC</given-names></string-name>, <string-name><surname>Collins</surname> <given-names>DL</given-names></string-name>. <article-title>Unbiased average age-appropriate atlases for pediatric studies</article-title>. <source>Neuroimage</source> <year>2011</year>;<volume>54</volume>:<fpage>313</fpage>–<lpage>327</lpage>.</mixed-citation></ref>
<ref id="c39"><label>39.</label><mixed-citation publication-type="journal"><string-name><surname>Shen</surname> <given-names>EH</given-names></string-name>, <string-name><surname>Overly</surname> <given-names>CC</given-names></string-name>, <string-name><surname>Jones</surname> <given-names>AR</given-names></string-name>. <article-title>The Allen Human Brain Atlas: comprehensive gene expression mapping of the human brain</article-title>. <source>Trends Neurosci</source> <year>2012</year>;<volume>35</volume>:<fpage>711</fpage>–<lpage>714</lpage>.</mixed-citation></ref>
<ref id="c40"><label>40.</label><mixed-citation publication-type="journal"><string-name><surname>Gryglewski</surname> <given-names>G</given-names></string-name>, <string-name><surname>Seiger</surname> <given-names>R</given-names></string-name>, <string-name><surname>James</surname> <given-names>GM</given-names></string-name>, <etal>et al.</etal> <article-title>Spatial analysis and high resolution mapping of the human whole-brain transcriptome for integrative analysis in neuroimaging</article-title>. <source>Neuroimage</source> <year>2018</year>;<volume>176</volume>:<fpage>259</fpage>–<lpage>267</lpage>.</mixed-citation></ref>
<ref id="c41"><label>41.</label><mixed-citation publication-type="journal"><string-name><surname>McKenzie</surname> <given-names>AT</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>M</given-names></string-name>, <string-name><surname>Hauberg</surname> <given-names>ME</given-names></string-name>, <etal>et al.</etal> <article-title>Brain Cell Type Specific Gene Expression and Co-expression Network Architectures</article-title>. <source>Sci Rep</source> <year>2018</year>;<volume>8</volume>:<fpage>8868</fpage>.</mixed-citation></ref>
<ref id="c42"><label>42.</label><mixed-citation publication-type="journal"><string-name><surname>Tzourio-Mazoyer</surname> <given-names>N</given-names></string-name>, <string-name><surname>Landeau</surname> <given-names>B</given-names></string-name>, <string-name><surname>Papathanassiou</surname> <given-names>D</given-names></string-name>, <etal>et al.</etal> <article-title>Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain</article-title>. <source>Neuroimage</source> <year>2002</year>;<volume>15</volume>:<fpage>273</fpage>–<lpage>289</lpage>.</mixed-citation></ref>
<ref id="c43"><label>43.</label><mixed-citation publication-type="journal"><string-name><surname>Desikan</surname> <given-names>RS</given-names></string-name>, <string-name><surname>Ségonne</surname> <given-names>F</given-names></string-name>, <string-name><surname>Fischl</surname> <given-names>B</given-names></string-name>, <etal>et al.</etal> <article-title>An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest</article-title>. <source>Neuroimage</source> <year>2006</year>;<volume>31</volume>:<fpage>968</fpage>–<lpage>980</lpage>.</mixed-citation></ref>
<ref id="c44"><label>44.</label><mixed-citation publication-type="journal"><string-name><surname>Li</surname> <given-names>J</given-names></string-name>, <string-name><surname>Pan</surname> <given-names>L</given-names></string-name>, <string-name><surname>Pembroke</surname> <given-names>WG</given-names></string-name>, <etal>et al.</etal> <article-title>Conservation and divergence of vulnerability and responses to stressors between human and mouse astrocytes</article-title>. <source>Nat Commun</source> <year>2021</year>;<volume>12</volume>:<fpage>3958</fpage>.</mixed-citation></ref>
<ref id="c45"><label>45.</label><mixed-citation publication-type="journal"><string-name><surname>González-Reyes</surname> <given-names>RE</given-names></string-name>, <string-name><surname>Nava-Mesa</surname> <given-names>MO</given-names></string-name>, <string-name><surname>Vargas-Sánchez</surname> <given-names>K</given-names></string-name>, <string-name><surname>Ariza-Salamanca</surname> <given-names>D</given-names></string-name>, <string-name><surname>Mora-Muñoz</surname> <given-names>L.</given-names></string-name> <article-title>Involvement of Astrocytes in Alzheimer’s Disease from a Neuroinflammatory and Oxidative Stress Perspective</article-title>. <source>Front Mol Neurosci</source> <year>2017</year>;<volume>10</volume>:<fpage>427</fpage>.</mixed-citation></ref>
<ref id="c46"><label>46.</label><mixed-citation publication-type="journal"><string-name><surname>Preininger</surname> <given-names>MK</given-names></string-name>, <string-name><surname>Kaufer</surname> <given-names>D.</given-names></string-name> <article-title>Blood-Brain Barrier Dysfunction and Astrocyte Senescence as Reciprocal Drivers of Neuropathology in Aging</article-title>. <source>Int J Mol Sci</source> <year>2022</year>;<volume>23</volume>.</mixed-citation></ref>
<ref id="c47"><label>47.</label><mixed-citation publication-type="journal"><string-name><surname>Yang</surname> <given-names>P</given-names></string-name>, <string-name><surname>Min</surname> <given-names>X-L</given-names></string-name>, <string-name><surname>Mohammadi</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title>Endothelial Degeneration of Parkinson’s Disease is Related to Alpha-Synuclein Aggregation</article-title>. <source>Journal of Alzheimer’s Disease &amp; Parkinsonism</source> <year>2017</year>;<volume>7</volume>.</mixed-citation></ref>
<ref id="c48"><label>48.</label><mixed-citation publication-type="journal"><string-name><surname>Salmina</surname> <given-names>AB</given-names></string-name>, <string-name><surname>Inzhutova</surname> <given-names>AI</given-names></string-name>, <string-name><surname>Malinovskaya</surname> <given-names>NA</given-names></string-name>, <string-name><surname>Petrova</surname> <given-names>MM</given-names></string-name>. <article-title>Endothelial dysfunction and repair in Alzheimer-type neurodegeneration: neuronal and glial control</article-title>. <source>J Alzheimers Dis</source> <year>2010</year>;<volume>22</volume>:<fpage>17</fpage>–<lpage>36</lpage>.</mixed-citation></ref>
<ref id="c49"><label>49.</label><mixed-citation publication-type="journal"><string-name><surname>Kalaria</surname> <given-names>RN</given-names></string-name>. <article-title>Cerebrovascular degeneration is related to amyloid-beta protein deposition in Alzheimer’s disease</article-title>. <source>Ann N Y Acad Sci</source> <year>1997</year>;<volume>826</volume>:<fpage>263</fpage>–<lpage>271</lpage>.</mixed-citation></ref>
<ref id="c50"><label>50.</label><mixed-citation publication-type="journal"><string-name><surname>Procter</surname> <given-names>TV</given-names></string-name>, <string-name><surname>Williams</surname> <given-names>A</given-names></string-name>, <string-name><surname>Montagne</surname> <given-names>A.</given-names></string-name> <article-title>Interplay between Brain Pericytes and Endothelial Cells in Dementia</article-title>. <source>Am J Pathol</source> <year>2021</year>;<volume>191</volume>:<fpage>1917</fpage>–<lpage>1931</lpage>.</mixed-citation></ref>
<ref id="c51"><label>51.</label><mixed-citation publication-type="journal"><string-name><surname>Geloso</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Corvino</surname> <given-names>V</given-names></string-name>, <string-name><surname>Marchese</surname> <given-names>E</given-names></string-name>, <string-name><surname>Serrano</surname> <given-names>A</given-names></string-name>, <string-name><surname>Michetti</surname> <given-names>F</given-names></string-name>, <string-name><surname>D’Ambrosi</surname> <given-names>N.</given-names></string-name> <article-title>The Dual Role of Microglia in ALS: Mechanisms and Therapeutic Approaches</article-title>. <source>Front Aging Neurosci</source> <year>2017</year>;<volume>9</volume>:<fpage>242</fpage>.</mixed-citation></ref>
<ref id="c52"><label>52.</label><mixed-citation publication-type="journal"><string-name><surname>Malpetti</surname> <given-names>M</given-names></string-name>, <string-name><surname>Jones</surname> <given-names>PS</given-names></string-name>, <string-name><surname>Hezemans</surname> <given-names>FH</given-names></string-name>, <etal>et al.</etal> <article-title>Microglial activation and atrophy in frontal cortex predict executive dysfunction in frontotemporal dementia</article-title>. <source>Alzheimer’s &amp; Dementia</source> <year>2022</year>;<volume>17</volume>.</mixed-citation></ref>
<ref id="c53"><label>53.</label><mixed-citation publication-type="journal"><string-name><surname>Perea</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Llorens-Martin</surname> <given-names>M</given-names></string-name>, <string-name><surname>Avila</surname> <given-names>J</given-names></string-name>, <string-name><surname>Bolos</surname> <given-names>M.</given-names></string-name> <article-title>The Role of Microglia in the Spread of Tau: Relevance for Tauopathies</article-title>. <source>Front Cell Neurosci</source> <year>2018</year>;<volume>12</volume>:<fpage>172</fpage>.</mixed-citation></ref>
<ref id="c54"><label>54.</label><mixed-citation publication-type="journal"><string-name><surname>Keren-Shaul</surname> <given-names>H</given-names></string-name>, <string-name><surname>Spinrad</surname> <given-names>A</given-names></string-name>, <string-name><surname>Weiner</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal> <article-title>A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease</article-title>. <source>Cell</source> <year>2017</year>;<volume>169</volume>:<fpage>1276</fpage>–<lpage>1290 e1217</lpage>.</mixed-citation></ref>
<ref id="c55"><label>55.</label><mixed-citation publication-type="journal"><string-name><surname>Vandenbark</surname> <given-names>AA</given-names></string-name>, <string-name><surname>Offner</surname> <given-names>H</given-names></string-name>, <string-name><surname>Matejuk</surname> <given-names>S</given-names></string-name>, <string-name><surname>Matejuk</surname> <given-names>A.</given-names></string-name> <article-title>Microglia and astrocyte involvement in neurodegeneration and brain cancer</article-title>. <source>J Neuroinflammation</source> <year>2021</year>;<volume>18</volume>:<fpage>298</fpage>.</mixed-citation></ref>
<ref id="c56"><label>56.</label><mixed-citation publication-type="journal"><string-name><surname>Zhou</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Song</surname> <given-names>WM</given-names></string-name>, <string-name><surname>Andhey</surname> <given-names>PS</given-names></string-name>, <etal>et al.</etal> <article-title>Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease</article-title>. <source>Nat Med</source> <year>2020</year>;<volume>26</volume>:<fpage>131</fpage>–<lpage>142</lpage>.</mixed-citation></ref>
<ref id="c57"><label>57.</label><mixed-citation publication-type="journal"><string-name><surname>Hu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Fryatt</surname> <given-names>GL</given-names></string-name>, <string-name><surname>Ghorbani</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title>Replicative senescence dictates the emergence of disease-associated microglia and contributes to Abeta pathology</article-title>. <source>Cell Rep</source> <year>2021</year>;<volume>35</volume>:<fpage>109228</fpage>.</mixed-citation></ref>
<ref id="c58"><label>58.</label><mixed-citation publication-type="journal"><string-name><surname>Streit</surname> <given-names>WJ</given-names></string-name>, <string-name><surname>Khoshbouei</surname> <given-names>H</given-names></string-name>, <string-name><surname>Bechmann</surname> <given-names>I.</given-names></string-name> <article-title>Dystrophic microglia in late-onset Alzheimer’s disease</article-title>. <source>Glia</source> <year>2020</year>;<volume>68</volume>:<fpage>845</fpage>–<lpage>854</lpage>.</mixed-citation></ref>
<ref id="c59"><label>59.</label><mixed-citation publication-type="other"><string-name><surname>Balusu</surname> <given-names>S</given-names></string-name>, <string-name><surname>Praschberger</surname> <given-names>R</given-names></string-name>, <string-name><surname>Lauwers</surname> <given-names>E</given-names></string-name>, <string-name><surname>De Strooper</surname> <given-names>B</given-names></string-name>, <string-name><surname>Verstreken</surname> <given-names>P.</given-names></string-name> <article-title>Neurodegeneration cell per cell</article-title>. <source>Neuron</source> <year>2023</year>.</mixed-citation></ref>
<ref id="c60"><label>60.</label><mixed-citation publication-type="journal"><string-name><surname>Lau</surname> <given-names>V</given-names></string-name>, <string-name><surname>Ramer</surname> <given-names>L</given-names></string-name>, <string-name><surname>Tremblay</surname> <given-names>M.</given-names></string-name> <article-title>An aging, pathology burden, and glial senescence build-up hypothesis for late onset Alzheimer’s disease</article-title>. <source>Nat Commun</source> <year>2023</year>;<volume>14</volume>:<fpage>1670</fpage>.</mixed-citation></ref>
<ref id="c61"><label>61.</label><mixed-citation publication-type="journal"><string-name><surname>Armada-Moreira</surname> <given-names>A</given-names></string-name>, <string-name><surname>Ribeiro</surname> <given-names>FF</given-names></string-name>, <string-name><surname>Sebastião</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Xapelli</surname> <given-names>S.</given-names></string-name> <article-title>Neuroinflammatory modulators of oligodendrogenesis</article-title>. <source>Neuroimmunology and Neuroinflammation</source> <year>2015</year>;<volume>2</volume>:<fpage>263</fpage>–<lpage>273</lpage>.</mixed-citation></ref>
<ref id="c62"><label>62.</label><mixed-citation publication-type="journal"><string-name><surname>Mot</surname> <given-names>AI</given-names></string-name>, <string-name><surname>Depp</surname> <given-names>C</given-names></string-name>, <string-name><surname>Nave</surname> <given-names>KA</given-names></string-name>. <article-title>An emerging role of dysfunctional axon-oligodendrocyte coupling in neurodegenerative diseases</article-title>. <source>Dialogues Clin Neurosci</source> <year>2018</year>;<volume>20</volume>:<fpage>283</fpage>–<lpage>292</lpage>.</mixed-citation></ref>
<ref id="c63"><label>63.</label><mixed-citation publication-type="journal"><string-name><surname>Bryois</surname> <given-names>J</given-names></string-name>, <string-name><surname>Skene</surname> <given-names>NG</given-names></string-name>, <string-name><surname>Hansen</surname> <given-names>TF</given-names></string-name>, <etal>et al.</etal> <article-title>Genetic identification of cell types underlying brain complex traits yields insights into the etiology of Parkinson’s disease</article-title>. <source>Nat Genet</source> <year>2020</year>;<volume>52</volume>:<fpage>482</fpage>–<lpage>493</lpage>.</mixed-citation></ref>
<ref id="c64"><label>64.</label><mixed-citation publication-type="journal"><string-name><surname>Feleke</surname> <given-names>R</given-names></string-name>, <string-name><surname>Reynolds</surname> <given-names>RH</given-names></string-name>, <string-name><surname>Smith</surname> <given-names>AM</given-names></string-name>, <etal>et al.</etal> <article-title>Cross-platform transcriptional profiling identifies common and distinct molecular pathologies in Lewy body diseases</article-title>. <source>Acta Neuropathol</source> <year>2021</year>;<volume>142</volume>:<fpage>449</fpage>–<lpage>474</lpage>.</mixed-citation></ref>
<ref id="c65"><label>65.</label><mixed-citation publication-type="journal"><string-name><surname>Agarwal</surname> <given-names>D</given-names></string-name>, <string-name><surname>Sandor</surname> <given-names>C</given-names></string-name>, <string-name><surname>Volpato</surname> <given-names>V</given-names></string-name>, <etal>et al.</etal> <article-title>A single-cell atlas of the human substantia nigra reveals cell-specific pathways associated with neurological disorders</article-title>. <source>Nat Commun</source> <year>2020</year>;<volume>11</volume>:<fpage>4183</fpage>.</mixed-citation></ref>
<ref id="c66"><label>66.</label><mixed-citation publication-type="journal"><string-name><surname>Orimo</surname> <given-names>S</given-names></string-name>, <string-name><surname>Uchihara</surname> <given-names>T</given-names></string-name>, <string-name><surname>Kanazawa</surname> <given-names>T</given-names></string-name>, <etal>et al.</etal> <article-title>Unmyelinated axons are more vulnerable to degeneration than myelinated axons of the cardiac nerve in Parkinson’s disease</article-title>. <source>Neuropathol Appl Neurobiol</source> <year>2011</year>;<volume>37</volume>:<fpage>791</fpage>–<lpage>802</lpage>.</mixed-citation></ref>
<ref id="c67"><label>67.</label><mixed-citation publication-type="journal"><string-name><surname>Wakabayashi</surname> <given-names>K</given-names></string-name>, <string-name><surname>Hayashi</surname> <given-names>S</given-names></string-name>, <string-name><surname>Yoshimoto</surname> <given-names>M</given-names></string-name>, <string-name><surname>Kudo</surname> <given-names>H</given-names></string-name>, <string-name><surname>Takahashi</surname> <given-names>H.</given-names></string-name> <article-title>NACP/alpha-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson’s disease brains</article-title>. <source>Acta Neuropathol</source> <year>2000</year>;<volume>99</volume>:<fpage>14</fpage>–<lpage>20</lpage>.</mixed-citation></ref>
<ref id="c68"><label>68.</label><mixed-citation publication-type="other"><string-name><surname>Palhol</surname> <given-names>JSC</given-names></string-name>, <string-name><surname>Balia</surname> <given-names>M</given-names></string-name>, <string-name><surname>Terán</surname> <given-names>FS-R</given-names></string-name>, <string-name><surname>Labarchède</surname> <given-names>M</given-names></string-name>, <string-name><surname>Gontier</surname> <given-names>E</given-names></string-name>, <string-name><surname>Battefeld</surname> <given-names>A.</given-names></string-name> <article-title>A population of gray matter oligodendrocytes directly associates with the vasculature</article-title>. <source>bioRxiv preprint</source> <year>2022</year>.</mixed-citation></ref>
<ref id="c69"><label>69.</label><mixed-citation publication-type="journal"><string-name><surname>Arai</surname> <given-names>K</given-names></string-name>, <string-name><surname>Lo</surname> <given-names>EH</given-names></string-name>. <article-title>An oligovascular niche: cerebral endothelial cells promote the survival and proliferation of oligodendrocyte precursor cells</article-title>. <source>J Neurosci</source> <year>2009</year>;<volume>29</volume>:<fpage>4351</fpage>–<lpage>4355</lpage>.</mixed-citation></ref>
<ref id="c70"><label>70.</label><mixed-citation publication-type="journal"><string-name><surname>Mathys</surname> <given-names>H</given-names></string-name>, <string-name><surname>Davila-Velderrain</surname> <given-names>J</given-names></string-name>, <string-name><surname>Peng</surname> <given-names>Z</given-names></string-name>, <etal>et al.</etal> <article-title>Single-cell transcriptomic analysis of Alzheimer’s disease</article-title>. <source>Nature</source> <year>2019</year>;<volume>570</volume>:<fpage>332</fpage>–<lpage>337</lpage>.</mixed-citation></ref>
<ref id="c71"><label>71.</label><mixed-citation publication-type="journal"><string-name><surname>Ohtomo</surname> <given-names>R</given-names></string-name>, <string-name><surname>Iwata</surname> <given-names>A</given-names></string-name>, <string-name><surname>Arai</surname> <given-names>K.</given-names></string-name> <article-title>Molecular Mechanisms of Oligodendrocyte Regeneration in White Matter-Related Diseases</article-title>. <source>Int J Mol Sci</source> <year>2018</year>;<volume>19</volume>.</mixed-citation></ref>
<ref id="c72"><label>72.</label><mixed-citation publication-type="journal"><string-name><surname>Traiffort</surname> <given-names>E</given-names></string-name>, <string-name><surname>Morisset-Lopez</surname> <given-names>S</given-names></string-name>, <string-name><surname>Moussaed</surname> <given-names>M</given-names></string-name>, <string-name><surname>Zahaf</surname> <given-names>A.</given-names></string-name> <article-title>Defective Oligodendroglial Lineage and Demyelination in Amyotrophic Lateral Sclerosis</article-title>. <source>Int J Mol Sci</source> <year>2021</year>;<volume>22</volume>.</mixed-citation></ref>
<ref id="c73"><label>73.</label><mixed-citation publication-type="journal"><string-name><surname>Spaas</surname> <given-names>J</given-names></string-name>, <string-name><surname>van Veggel</surname> <given-names>L</given-names></string-name>, <string-name><surname>Schepers</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title>Oxidative stress and impaired oligodendrocyte precursor cell differentiation in neurological disorders</article-title>. <source>Cell Mol Life Sci</source> <year>2021</year>;<volume>78</volume>:<fpage>4615</fpage>–<lpage>4637</lpage>.</mixed-citation></ref>
<ref id="c74"><label>74.</label><mixed-citation publication-type="journal"><string-name><surname>Heo</surname> <given-names>D</given-names></string-name>, <string-name><surname>Ling</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Molina-Castro</surname> <given-names>GC</given-names></string-name>, <etal>et al.</etal> <article-title>Stage-specific control of oligodendrocyte survival and morphogenesis by TDP-43</article-title>. <source>Elife</source> <year>2022</year>;<volume>11</volume>.</mixed-citation></ref>
<ref id="c75"><label>75.</label><mixed-citation publication-type="journal"><string-name><surname>Wang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Ho</surname> <given-names>WY</given-names></string-name>, <string-name><surname>Lim</surname> <given-names>K</given-names></string-name>, <etal>et al.</etal> <article-title>Cell-autonomous requirement of TDP-43, an ALS/FTD signature protein, for oligodendrocyte survival and myelination</article-title>. <source>Proc Natl Acad Sci U S A</source> <year>2018</year>;<volume>115</volume>:<fpage>E10941</fpage>–<lpage>e10950</lpage>.</mixed-citation></ref>
<ref id="c76"><label>76.</label><mixed-citation publication-type="journal"><string-name><surname>Kim</surname> <given-names>WS</given-names></string-name>, <string-name><surname>Kågedal</surname> <given-names>K</given-names></string-name>, <string-name><surname>Halliday</surname> <given-names>GM</given-names></string-name>. <article-title>Alpha-synuclein biology in Lewy body diseases</article-title>. <source>Alzheimers Res Ther</source> <year>2014</year>;<volume>6</volume>:<fpage>73</fpage>.</mixed-citation></ref>
<ref id="c77"><label>77.</label><mixed-citation publication-type="journal"><string-name><surname>Howlett</surname> <given-names>DR</given-names></string-name>, <string-name><surname>Whitfield</surname> <given-names>D</given-names></string-name>, <string-name><surname>Johnson</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title>Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias</article-title>. <source>Brain Pathol</source> <year>2015</year>;<volume>25</volume>:<fpage>401</fpage>–<lpage>408</lpage>.</mixed-citation></ref>
<ref id="c78"><label>78.</label><mixed-citation publication-type="journal"><string-name><surname>Burton</surname> <given-names>EJ</given-names></string-name>, <string-name><surname>McKeith</surname> <given-names>IG</given-names></string-name>, <string-name><surname>Burn</surname> <given-names>DJ</given-names></string-name>, <string-name><surname>Williams</surname> <given-names>ED</given-names></string-name>, <string-name><surname>O’Brien</surname> <given-names>JT</given-names></string-name>. <article-title>Cerebral atrophy in Parkinson’s disease with and without dementia: a comparison with Alzheimer’s disease, dementia with Lewy bodies and controls</article-title>. <source>Brain</source> <year>2004</year>;<volume>127</volume>:<fpage>791</fpage>–<lpage>800</lpage>.</mixed-citation></ref>
<ref id="c79"><label>79.</label><mixed-citation publication-type="journal"><string-name><surname>Mackenzie</surname> <given-names>IR</given-names></string-name>, <string-name><surname>Rademakers</surname> <given-names>R.</given-names></string-name> <article-title>The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementia</article-title>. <source>Curr Opin Neurol</source> <year>2008</year>;<volume>21</volume>:<fpage>693</fpage>–<lpage>700</lpage>.</mixed-citation></ref>
<ref id="c80"><label>80.</label><mixed-citation publication-type="journal"><string-name><surname>Ferrari</surname> <given-names>R</given-names></string-name>, <string-name><surname>Kapogiannis</surname> <given-names>D</given-names></string-name>, <string-name><surname>Huey</surname> <given-names>ED</given-names></string-name>, <string-name><surname>Momeni</surname> <given-names>P.</given-names></string-name> <article-title>FTD and ALS: a tale of two diseases</article-title>. <source>Curr Alzheimer Res</source> <year>2011</year>;<volume>8</volume>:<fpage>273</fpage>–<lpage>294</lpage>.</mixed-citation></ref>
<ref id="c81"><label>81.</label><mixed-citation publication-type="journal"><string-name><surname>Iturria-Medina</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Evans</surname> <given-names>AC</given-names></string-name>. <article-title>On the central role of brain connectivity in neurodegenerative disease progression</article-title>. <source>Front Aging Neurosci</source> <year>2015</year>;<volume>7</volume>:<fpage>90</fpage>.</mixed-citation></ref>
<ref id="c82"><label>82.</label><mixed-citation publication-type="journal"><string-name><surname>Tremblay</surname> <given-names>C</given-names></string-name>, <string-name><surname>Rahayel</surname> <given-names>S</given-names></string-name>, <string-name><surname>Vo</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal> <article-title>Brain atrophy progression in Parkinson’s disease is shaped by connectivity and local vulnerability</article-title>. <source>Brain Commun</source> <year>2021</year>;<volume>3</volume>:<fpage>fcab269</fpage>.</mixed-citation></ref>
<ref id="c83"><label>83.</label><mixed-citation publication-type="journal"><string-name><surname>Zeighami</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Ulla</surname> <given-names>M</given-names></string-name>, <string-name><surname>Iturria-Medina</surname> <given-names>Y</given-names></string-name>, <etal>et al.</etal> <article-title>Network structure of brain atrophy in de novo Parkinson’s disease</article-title>. <source>Elife</source> <year>2015</year>;<volume>4</volume>.</mixed-citation></ref>
<ref id="c84"><label>84.</label><mixed-citation publication-type="journal"><string-name><surname>Liddelow</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Guttenplan</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Clarke</surname> <given-names>LE</given-names></string-name>, <etal>et al.</etal> <article-title>Neurotoxic reactive astrocytes are induced by activated microglia</article-title>. <source>Nature</source> <year>2017</year>;<volume>541</volume>:<fpage>481</fpage>–<lpage>487</lpage>.</mixed-citation></ref>
<ref id="c85"><label>85.</label><mixed-citation publication-type="journal"><string-name><surname>Yun</surname> <given-names>SP</given-names></string-name>, <string-name><surname>Kam</surname> <given-names>TI</given-names></string-name>, <string-name><surname>Panicker</surname> <given-names>N</given-names></string-name>, <etal>et al.</etal> <article-title>Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease</article-title>. <source>Nat Med</source> <year>2018</year>;<volume>24</volume>:<fpage>931</fpage>–<lpage>938</lpage>.</mixed-citation></ref>
<ref id="c86"><label>86.</label><mixed-citation publication-type="journal"><string-name><surname>Arnatkeviciute</surname> <given-names>A</given-names></string-name>, <string-name><surname>Fulcher</surname> <given-names>BD</given-names></string-name>, <string-name><surname>Fornito</surname> <given-names>A.</given-names></string-name> <article-title>A practical guide to linking brain-wide gene expression and neuroimaging data</article-title>. <source>Neuroimage</source> <year>2019</year>;<volume>189</volume>:<fpage>353</fpage>–<lpage>367</lpage>.</mixed-citation></ref>
<ref id="c87"><label>87.</label><mixed-citation publication-type="journal"><string-name><surname>Jackson</surname> <given-names>WS</given-names></string-name>. <article-title>Selective vulnerability to neurodegenerative disease: the curious case of Prion Protein</article-title>. <source>Dis Model Mech</source> <year>2014</year>;<volume>7</volume>:<fpage>21</fpage>–<lpage>29</lpage>.</mixed-citation></ref>
<ref id="c88"><label>88.</label><mixed-citation publication-type="journal"><string-name><surname>Lau</surname> <given-names>SF</given-names></string-name>, <string-name><surname>Cao</surname> <given-names>H</given-names></string-name>, <string-name><surname>Fu</surname> <given-names>AKY</given-names></string-name>, <string-name><surname>Ip</surname> <given-names>NY</given-names></string-name>. <article-title>Single-nucleus transcriptome analysis reveals dysregulation of angiogenic endothelial cells and neuroprotective glia in Alzheimer’s disease</article-title>. <source>Proc Natl Acad Sci U S A</source> <year>2020</year>;<volume>117</volume>:<fpage>25800</fpage>–<lpage>25809</lpage>.</mixed-citation></ref>
<ref id="c89"><label>89.</label><mixed-citation publication-type="journal"><string-name><surname>Johnson</surname> <given-names>TS</given-names></string-name>, <string-name><surname>Xiang</surname> <given-names>S</given-names></string-name>, <string-name><surname>Dong</surname> <given-names>T</given-names></string-name>, <etal>et al.</etal> <article-title>Combinatorial analyses reveal cellular composition changes have different impacts on transcriptomic changes of cell type specific genes in Alzheimer’s Disease</article-title>. <source>Sci Rep</source> <year>2021</year>;<volume>11</volume>:<fpage>353</fpage>.</mixed-citation></ref>
<ref id="c90"><label>90.</label><mixed-citation publication-type="journal"><string-name><surname>Wang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Allen</surname> <given-names>M</given-names></string-name>, <string-name><surname>Li</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal> <article-title>Deciphering cellular transcriptional alterations in Alzheimer’s disease brains</article-title>. <source>Mol Neurodegener</source> <year>2020</year>;<volume>15</volume>:<fpage>38</fpage>.</mixed-citation></ref>
<ref id="c91"><label>91.</label><mixed-citation publication-type="journal"><string-name><surname>Nido</surname> <given-names>GS</given-names></string-name>, <string-name><surname>Dick</surname> <given-names>F</given-names></string-name>, <string-name><surname>Toker</surname> <given-names>L</given-names></string-name>, <etal>et al.</etal> <article-title>Common gene expression signatures in Parkinson’s disease are driven by changes in cell composition</article-title>. <source>Acta Neuropathol Commun</source> <year>2020</year>;<volume>8</volume>:<fpage>55</fpage>.</mixed-citation></ref>
<ref id="c92"><label>92.</label><mixed-citation publication-type="other"><string-name><surname>Zeng</surname> <given-names>H</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>H</given-names></string-name>, <etal>et al.</etal> <article-title>Integrative in situ mapping of single-cell transcriptional states and tissue histopathology in a mouse model of Alzheimer’s disease</article-title>. <source>Nat Neurosci</source> <year>2023</year>.</mixed-citation></ref>
<ref id="c93"><label>93.</label><mixed-citation publication-type="journal"><string-name><surname>Grubman</surname> <given-names>A</given-names></string-name>, <string-name><surname>Chew</surname> <given-names>G</given-names></string-name>, <string-name><surname>Ouyang</surname> <given-names>JF</given-names></string-name>, <etal>et al.</etal> <article-title>A single-cell atlas of entorhinal cortex from individuals with Alzheimer’s disease reveals cell-type-specific gene expression regulation</article-title>. <source>Nat Neurosci</source> <year>2019</year>;<volume>22</volume>:<fpage>2087</fpage>–<lpage>2097</lpage>.</mixed-citation></ref>
<ref id="c94"><label>94.</label><mixed-citation publication-type="journal"><string-name><surname>Murdock</surname> <given-names>MH</given-names></string-name>, <string-name><surname>Tsai</surname> <given-names>LH</given-names></string-name>. <article-title>Insights into Alzheimer’s disease from single-cell genomic approaches</article-title>. <source>Nat Neurosci</source> <year>2023</year>;<volume>26</volume>:<fpage>181</fpage>–<lpage>195</lpage>.</mixed-citation></ref>
<ref id="c95"><label>95.</label><mixed-citation publication-type="journal"><string-name><surname>Andrade-Moraes</surname> <given-names>CH</given-names></string-name>, <string-name><surname>Oliveira-Pinto</surname> <given-names>AV</given-names></string-name>, <string-name><surname>Castro-Fonseca</surname> <given-names>E</given-names></string-name>, <etal>et al.</etal> <article-title>Cell number changes in Alzheimer’s disease relate to dementia, not to plaques and tangles</article-title>. <source>Brain</source> <year>2013</year>;<volume>136</volume>:<fpage>3738</fpage>–<lpage>3752</lpage>.</mixed-citation></ref>
<ref id="c96"><label>96.</label><mixed-citation publication-type="journal"><string-name><surname>Iturria-Medina</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Hachinski</surname> <given-names>V</given-names></string-name>, <string-name><surname>Evans</surname> <given-names>AC</given-names></string-name>. <article-title>The vascular facet of late-onset Alzheimer’s disease: an essential factor in a complex multifactorial disorder</article-title>. <source>Curr Opin Neurol</source> <year>2017</year>;<volume>30</volume>:<fpage>623</fpage>–<lpage>629</lpage>.</mixed-citation></ref>
<ref id="c97"><label>97.</label><mixed-citation publication-type="journal"><string-name><surname>Iturria-Medina</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Carbonell</surname> <given-names>FM</given-names></string-name>, <string-name><surname>Sotero</surname> <given-names>RC</given-names></string-name>, <string-name><surname>Chouinard-Decorte</surname> <given-names>F</given-names></string-name>, <string-name><surname>Evans</surname> <given-names>AC</given-names></string-name>, <collab>Alzheimer’s Disease Neuroimaging I</collab>. <article-title>Multifactorial causal model of brain (dis)organization and therapeutic intervention: Application to Alzheimer’s disease</article-title>. <source>Neuroimage</source> <year>2017</year>;<volume>152</volume>:<fpage>60</fpage>–<lpage>77</lpage>.</mixed-citation></ref>
<ref id="c98"><label>98.</label><mixed-citation publication-type="journal"><string-name><surname>Iturria-Medina</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Sotero</surname> <given-names>RC</given-names></string-name>, <string-name><surname>Toussaint</surname> <given-names>PJ</given-names></string-name>, <string-name><surname>Mateos-Perez</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Evans</surname> <given-names>AC</given-names></string-name>, <collab>Alzheimer’s Disease Neuroimaging I</collab>. <article-title>Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis</article-title>. <source>Nat Commun</source> <year>2016</year>;<volume>7</volume>:<fpage>11934</fpage>.</mixed-citation></ref>
<ref id="c99"><label>99.</label><mixed-citation publication-type="journal"><string-name><surname>Fonov</surname> <given-names>VS</given-names></string-name>, <string-name><surname>Dadar</surname> <given-names>M</given-names></string-name>, <string-name><surname>Manera</surname> <given-names>AL</given-names></string-name>, <string-name><surname>Ducharme</surname> <given-names>S</given-names></string-name>, <string-name><surname>Collins</surname> <given-names>L.</given-names></string-name> <article-title>Clinical subtypes of frontotemporal dementia show different patterns of cortical atrophy</article-title>. <source>Alzheimer’s &amp; Dementia</source> <year>2021</year>;<volume>17</volume>.</mixed-citation></ref>
<ref id="c100"><label>100.</label><mixed-citation publication-type="journal"><string-name><surname>Rosenberg-Katz</surname> <given-names>K</given-names></string-name>, <string-name><surname>Herman</surname> <given-names>T</given-names></string-name>, <string-name><surname>Jacob</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Giladi</surname> <given-names>N</given-names></string-name>, <string-name><surname>Hendler</surname> <given-names>T</given-names></string-name>, <string-name><surname>Hausdorff</surname> <given-names>JM</given-names></string-name>. <article-title>Gray matter atrophy distinguishes between Parkinson disease motor subtypes</article-title>. <source>Neurology</source> <year>2013</year>;<volume>80</volume>:<fpage>1476</fpage>–<lpage>1484</lpage>.</mixed-citation></ref>
<ref id="c101"><label>101.</label><mixed-citation publication-type="other"><string-name><surname>Dai</surname> <given-names>R</given-names></string-name>, <string-name><surname>Chu</surname> <given-names>T</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title>Evaluating performance and applications of sample-wise cell deconvolution methods on human brain transcriptomic data</article-title>. <source>bioRxiv</source> <year>2023</year>.</mixed-citation></ref>
<ref id="c102"><label>102.</label><mixed-citation publication-type="journal"><string-name><surname>Iturria-Medina</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Khan</surname> <given-names>AF</given-names></string-name>, <string-name><surname>Adewale</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Shirazi</surname> <given-names>AH</given-names></string-name>, <collab>Alzheimer’s Disease Neuroimaging I</collab>. <article-title>Blood and brain gene expression trajectories mirror neuropathology and clinical deterioration in neurodegeneration</article-title>. <source>Brain</source> <year>2020</year>;<volume>143</volume>:<fpage>661</fpage>–<lpage>673</lpage>.</mixed-citation></ref>
<ref id="c103"><label>103.</label><mixed-citation publication-type="journal"><string-name><surname>Hammond</surname> <given-names>TR</given-names></string-name>, <string-name><surname>Dufort</surname> <given-names>C</given-names></string-name>, <string-name><surname>Dissing-Olesen</surname> <given-names>L</given-names></string-name>, <etal>et al.</etal> <article-title>Single-Cell RNA Sequencing of Microglia throughout the Mouse Lifespan and in the Injured Brain Reveals Complex Cell-State Changes</article-title>. <source>Immunity</source> <year>2019</year>;<volume>50</volume>:<fpage>253</fpage>–<lpage>271</lpage>.e256.</mixed-citation></ref>
<ref id="c104"><label>104.</label><mixed-citation publication-type="journal"><string-name><surname>Jaffe</surname> <given-names>AE</given-names></string-name>, <string-name><surname>Tao</surname> <given-names>R</given-names></string-name>, <string-name><surname>Norris</surname> <given-names>AL</given-names></string-name>, <etal>et al.</etal> <article-title>qSVA framework for RNA quality correction in differential expression analysis</article-title>. <source>Proc Natl Acad Sci U S A</source> <year>2017</year>;<volume>114</volume>:<fpage>7130</fpage>–<lpage>7135</lpage>.</mixed-citation></ref>
<ref id="c105"><label>105.</label><mixed-citation publication-type="journal"><string-name><surname>Yu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Abbas-Aghababazadeh</surname> <given-names>F</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>YA</given-names></string-name>, <string-name><surname>Fridley</surname> <given-names>BL</given-names></string-name>. <article-title>Statistical and Bioinformatics Analysis of Data from Bulk and Single-Cell RNA Sequencing Experiments</article-title>. <source>Methods Mol Biol</source> <year>2021</year>;<volume>2194</volume>:<fpage>143</fpage>–<lpage>175</lpage>.</mixed-citation></ref>
<ref id="c106"><label>106.</label><mixed-citation publication-type="journal"><string-name><surname>Whitwell</surname> <given-names>JL</given-names></string-name>. <article-title>Voxel-based morphometry: an automated technique for assessing structural changes in the brain</article-title>. <source>J Neurosci</source> <year>2009</year>;<volume>29</volume>:<fpage>9661</fpage>–<lpage>9664</lpage>.</mixed-citation></ref>
<ref id="c107"><label>107.</label><mixed-citation publication-type="journal"><string-name><surname>Chung</surname> <given-names>MK</given-names></string-name>, <string-name><surname>Worsley</surname> <given-names>KJ</given-names></string-name>, <string-name><surname>Paus</surname> <given-names>T</given-names></string-name>, <etal>et al.</etal> <article-title>A unified statistical approach to deformation-based morphometry</article-title>. <source>Neuroimage</source> <year>2001</year>;<volume>14</volume>:<fpage>595</fpage>–<lpage>606</lpage>.</mixed-citation></ref>
<ref id="c108"><label>108.</label><mixed-citation publication-type="journal"><string-name><surname>Dadar</surname> <given-names>M</given-names></string-name>, <string-name><surname>Manera</surname> <given-names>AL</given-names></string-name>, <string-name><surname>Zinman</surname> <given-names>L</given-names></string-name>, <etal>et al.</etal> <article-title>Cerebral atrophy in amyotrophic lateral sclerosis parallels the pathological distribution of TDP43</article-title>. <source>Brain Commun</source> <year>2020</year>;<volume>2</volume>:<fpage>fcaa061</fpage>.</mixed-citation></ref>
<ref id="c109"><label>109.</label><mixed-citation publication-type="journal"><string-name><surname>Dadar</surname> <given-names>M</given-names></string-name>, <string-name><surname>Manera</surname> <given-names>AL</given-names></string-name>, <string-name><surname>Ducharme</surname> <given-names>S</given-names></string-name>, <string-name><surname>Collins</surname> <given-names>DL</given-names></string-name>. <article-title>White matter hyperintensities are associated with grey matter atrophy and cognitive decline in Alzheimer’s disease and frontotemporal dementia</article-title>. <source>Neurobiol Aging</source> <year>2022</year>;<volume>111</volume>:<fpage>54</fpage>–<lpage>63</lpage>.</mixed-citation></ref>
</ref-list>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.89368.1.sa3</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Fornito</surname>
<given-names>Alex</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Monash University</institution>
</institution-wrap>
<city>Clayton</city>
<country>Australia</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Incomplete</kwd>
</kwd-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Valuable</kwd>
</kwd-group>
</front-stub>
<body>
<p>Pak et al. examined the relationship between the most common spatial patterns of neurodegeneration and the density of different cell types in the cerebral cortex. The study uses innovative methods but the main claims are <bold>incompletely</bold> supported due to some limitations. While the results might be considered preliminary, this work provides <bold>valuable</bold> findings and takes a step in the right direction by highlighting the contribution of non-neuronal cell type to the pathobiology of neurodegeneration.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.89368.1.sa2</article-id>
<title-group>
<article-title>Reviewer #1 (Public Review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>This study explores the relationship between the most common spatial patterns of neurodegeneration and the density of different cell types in the cerebral cortex. The authors present data showing that atrophy patterns in Alzheimer's disease and Frontotemporal dementia strongly associate with the abundance of astrocytes and microglia. While the results here may be considered preliminary, this work takes a step in the right direction by emphasizing the critical role that cells other than neurons play in the degeneration patterns observable with neuroimaging.</p>
<p>I have two main comments:</p>
<p>1. The authors make an important innovation by applying the cellular deconvolution approach to create brain-wide maps of cellular abundance, and then comparing these maps to atrophy patterns from the most common neurodegenerative diseases and dementia syndromes.</p>
<p>2. I would have preferred to see more figures with brain images showing the cellular abundance maps and the atrophy maps. Without being able to see these figures, it's difficult for the reader to 1) validate the atrophy patterns or 2) gain intuition about how the cellular abundance maps vary across the brain. The images in Figure 1C give a small preview, but I'd like to see these maps in their entirety on the brain surface or axial image slices.</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.89368.1.sa1</article-id>
<title-group>
<article-title>Reviewer #2 (Public Review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Pak et al. report on a study using a computational method to assess differences in the relative proportion of six canonical brain cell types, across eleven neurodegenerative classes (defined as both clinical syndromes (e.g. FTD, PD), groups of neurogenerative diseases (e.g. 4-repeat tauopathies) or distinct neuropathological entities (e.g. FTLD-TDP type C), as they relate to a standard map of class-dependent volume loss. The study uses innovative methods and is commendable in its goal to highlight the contribution of non-neuronal cell types to the pathobiology of neurodegeneration. The findings of the study are in part contradicting expected results based on extensive literature on the biology of these diseases. The authors based their methodology on the use of a deconvolutional cell classifier; however, do not extensively recognize that their data on gene expression are based on normal brain levels rather than on diseased ones. Also, while predicted levels are uniquely based on patterns of brain atrophy, it is not possible to know whether this strategy is generalizable to all diseases (for instance, it is known that pure DLB, PD and ALS are not associated with extensive brain atrophy), or even adequately comparable between subtypes of diseases within the same class (e.g., different forms of FTLD). The authors do not acknowledge that only data based on true neuropathological assessment may prove whether their findings are true. Subject characteristics, numbers, and diagnostic criteria are hard to assess and only described in the methods section. This format prevents the reader from assessing data robustness while going through the results, especially when fundamental biological bases of nomenclature and differences between clinical syndromes and pathological entities are omitted or uncharacteristically provided.</p>
</body>
</sub-article>
<sub-article id="sa3" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.89368.1.sa0</article-id>
<title-group>
<article-title>Reviewer #3 (Public Review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>This study is a fine example of a recent productive trend in the integration of neuroimaging and molecular biology of the brain: in brief, overlaying some neuroimaging data (usually from a large cohort) onto the high spatial resolution gene expression in the Allen Human Brain Atlas data, derived from 6 individuals. By projecting structural MRI images over cell type proportions identified in the Allen data, the authors can represent various diseases in terms of their spatially-associated cell types. The result has implications for prioritizing the contributions of various cell types to each disease and creates an even-handed cell type profile through which the 11 diseases can be compared.</p>
</body>
</sub-article>
</article>